,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,DEFB119,"DEFB-19, DEFB-20, DEFB120",ENSG00000180483,Defensin beta 119,20,31377164-31390603,Predicted secreted proteins,Evidence at protein level,HPA043059,Supported,,,,,Tissue enriched,Group enriched,3499,epididymis: 2335.6;testis: 472.8,duodenum: 0.4,Not detected,,
1,DEFB123,DEFB-23,ENSG00000180424,Defensin beta 123,20,31440519-31450257,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enriched,Group enriched,438,epididymis: 108.1;testis: 178.0,small intestine: 0.3,Not detected,,
2,RFX4,,ENSG00000111783,Regulatory factor X4,12,106582907-106762803,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA050527,Enhanced,,Approved,Nucleus,,Tissue enriched,Group enriched,236,cerebral cortex: 30.8;testis: 135.8,prostate: 0.3,Cell line enriched,13.0,AF22: 47.1
3,MAGEB3,CT3.5,ENSG00000198798,MAGE family member B3,X,30230436-30237492,Predicted intracellular proteins,Evidence at protein level,HPA072203,Approved,,,,,Not detected,Group enriched,156,epididymis: 21.5;testis: 9.5,all non-specific tissues: 0.0,Cell line enriched,10.0,U-266/70: 1.6
4,EPPIN,"CT71, dJ461P17.2, EPPIN1, EPPIN2, EPPIN3, SPINLW1, WAP7, WFDC7",ENSG00000101448,Epididymal peptidase inhibitor,20,45540626-45547752,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,117,epididymis: 414.2;testis: 128.4,fallopian tube: 2.3,Cell line enhanced,,U-87 MG: 2.6
5,MAGEB4,"CT3.6, MGC33144",ENSG00000120289,MAGE family member B4,X,30242052-30244193,Predicted intracellular proteins,Evidence at protein level,HPA030456,Enhanced,,,,,Not detected,Group enriched,117,epididymis: 34.1;testis: 17.0,breast: 0.2,Not detected,,
6,MMD2,PAQR10,ENSG00000136297,Monocyte to macrophage differentiation associated 2,7,4905989-4959213,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,83,cerebral cortex: 41.2;testis: 12.4,adrenal gland: 0.3,Not detected,,
7,EPPIN-WFDC6,SPINLW1-WFDC6,ENSG00000249139,EPPIN-WFDC6 readthrough,20,45536986-45547426,Predicted secreted proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,78,epididymis: 41.7;testis: 58.2,fallopian tube: 0.6,Not detected,,
8,GAGE2E,GAGE8,ENSG00000275113,G antigen 2E,X,49341192-49345922,Predicted intracellular proteins,Evidence at transcript level,HPA043232,Approved,,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,,Not detected,Group enriched,60,stomach: 15.4;testis: 8.6,small intestine: 0.2,Group enriched,5.0,AN3-CA: 943.7;K-562: 455.5;T-47d: 231.8
9,GBX1,,ENSG00000164900,Gastrulation brain homeobox 1,7,151148589-151174745,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA055783,Uncertain,,,,,Tissue enhanced,Group enriched,57,skeletal muscle: 4.4;testis: 6.9,all non-specific tissues: 0.0,Cell line enhanced,,HMC-1: 1.4
10,MCHR2,"GPR145, MCH2, MCH2R, SLT",ENSG00000152034,Melanin concentrating hormone receptor 2,6,99919910-99994247,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,47,cerebral cortex: 8.6;testis: 4.3,"colon,small intestine: 0.1",Not detected,,
11,ZIC5,,ENSG00000139800,Zic family member 5,13,99962964-99971909,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA074045,,,Uncertain,Nucleoplasm<br>Vesicles,,Mixed,Group enriched,45,cerebral cortex: 2.3;testis: 6.6,all non-specific tissues: 0.0,Cell line enhanced,,AF22: 21.7;NTERA-2: 15.0;SCLC-21H: 100.6
12,DNAJC5G,"CSP-gamma, FLJ40417",ENSG00000163793,DnaJ heat shock protein family (Hsp40) member C5 gamma,2,27275421-27281499,Predicted membrane proteins,Evidence at transcript level,HPA041445,Approved,,,,,Not detected,Group enriched,41,epididymis: 65.0;testis: 42.7,cerebral cortex: 1.3,Cell line enhanced,,HAP1: 1.0
13,DAZ4,,ENSG00000205916,Deleted in azoospermia 4,Y,24833843-24907040,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA047113,Approved,,,,,Not detected,Group enriched,40,stomach: 22.3;testis: 21.5,skin: 0.5,Group enriched,123.0,U-266/70: 117.1;U-266/84: 107.2
14,NAA11,"ARD1B, ARD2, hARD2",ENSG00000156269,"N(alpha)-acetyltransferase 11, NatA catalytic subunit",4,79225694-79326050,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA035922,Approved,,,,,Tissue enhanced,Group enriched,37,placenta: 6.1;testis: 11.4,"cerebral cortex,endometrium,parathyroid gland,smooth muscle,thyroid gland: 0.2",Cell line enhanced,,K-562: 11.1;U-266/70: 25.3;U-266/84: 8.0
15,PHF24,KIAA1045,ENSG00000122733,PHD finger protein 24,9,34957608-34982544,Predicted intracellular proteins,Evidence at protein level,HPA020974,Approved,,,,,Tissue enhanced,Group enriched,36,cerebral cortex: 58.6;testis: 25.9,skin: 1.1,Cell line enhanced,,WM-115: 1.1
16,POTEH,"A26C3, ACTBL1, CT104.7, POTE22",ENSG00000198062,POTE ankyrin domain family member H,22,15690026-15721631,Predicted intracellular proteins,Evidence at transcript level,HPA042822,Uncertain,,,,,Tissue enriched,Group enriched,36,prostate: 5.7;testis: 1.4,all non-specific tissues: 0.0,Cell line enhanced,,U-2 OS: 1.1
17,U82695.5,,ENSG00000214897,,X,153395640-153401420,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Group enriched,35,epididymis: 5.8;ovary: 4.7;testis: 10.9,fallopian tube: 0.2,Not detected,,
18,RP11-14J7.7,,ENSG00000259060,Probable ribonuclease 11 precursor ,14,20582892-20609795,Predicted secreted proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,34,epididymis: 5.4;testis: 1.2,all non-specific tissues: 0.0,Not detected,,
19,XX-FW81066F1.2,,ENSG00000283463,,X,149929645-149931287,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Group enriched,33,adrenal gland: 4.8;testis: 17.6,skin: 0.3,Not detected,,
20,ELAVL2,"HEL-N1, HuB",ENSG00000107105,ELAV like RNA binding protein 2,9,23690104-23826337,Predicted intracellular proteins,Evidence at protein level,"CAB022222, HPA063001",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Tissue enhanced,Group enriched,32,cerebral cortex: 37.9;testis: 80.3,adrenal gland: 1.8,Cell line enhanced,,AF22: 36.8;SCLC-21H: 145.6
21,TEX15,CT42,ENSG00000133863,"Testis expressed 15, meiosis and synapsis associated",8,30831544-30890606,Predicted intracellular proteins,Evidence at protein level,"HPA036799, HPA036800",Enhanced,,Approved,Nuclear speckles,,Not detected,Group enriched,32,endometrium: 11.0;smooth muscle: 8.3;testis: 22.3,"cerebral cortex,gallbladder: 0.4",Cell line enhanced,,HAP1: 8.7;HEL: 17.3;K-562: 4.9;SCLC-21H: 4.9
22,C1orf194,,ENSG00000179902,Chromosome 1 open reading frame 194,1,109105951-109113857,Predicted intracellular proteins,Evidence at protein level,"HPA031144, HPA049684",Enhanced,,Uncertain,Nuclear speckles<br>Cytosol,Endometrial cancer:1.36e-4 (favourable),Group enriched,Group enriched,31,fallopian tube: 198.1;testis: 199.1,lung: 6.4,Cell line enhanced,,AF22: 1.5;SCLC-21H: 2.5
23,CFAP206,"C6orf165, dJ382I10.1, FLJ25974",ENSG00000272514,Cilia and flagella associated protein 206,6,87407983-87464465,Predicted intracellular proteins,Evidence at protein level,"HPA044891, HPA072261",Approved,,Approved,Nucleoplasm<br>Cell Junctions,,Not detected,Group enriched,30,fallopian tube: 35.9;testis: 106.8,"lung,thyroid gland: 2.3",Cell line enhanced,,MCF7: 1.7;RPTEC TERT1: 2.0;T-47d: 4.2
24,EGR4,"NGFI-C, PAT133",ENSG00000135625,Early growth response 4,2,73290929-73293705,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA028983,Enhanced,,,,,Mixed,Group enriched,29,cerebral cortex: 9.7;testis: 3.2,"adipose tissue,appendix: 0.2",Cell line enriched,6.0,HMC-1: 1.4
25,HIPK4,FLJ32818,ENSG00000160396,Homeodomain interacting protein kinase 4,19,40379271-40390187,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027733,Uncertain,,,,,Not detected,Group enriched,29,cerebral cortex: 4.7;testis: 14.6,endometrium: 0.3,Not detected,,
26,AC133551.1,,ENSG00000274175,,Unmapped,17234-19833,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Group enriched,28,epididymis: 7.4;testis: 4.1,placenta: 0.2,Not detected,,
27,DAZ2,"MGC126442, pDP1678",ENSG00000205944,Deleted in azoospermia 2,Y,23219434-23291356,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA047113,Approved,,,,,Not detected,Group enriched,27,stomach: 15.5;testis: 7.2,skin: 0.4,Cell line enriched,9.0,SK-MEL-30: 1.4
28,SOHLH1,"bA100C15.3, bHLHe80, C9orf157, NOHLH, SPATA27, TEB2",ENSG00000165643,Spermatogenesis and oogenesis specific basic helix-loop-helix 1,9,135693407-135699528,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059439,,,Approved,Nuclear speckles,,Mixed,Group enriched,27,cerebral cortex: 6.3;testis: 13.4,skin: 0.3,Group enriched,36.0,CACO-2: 14.6;U-266/84: 19.8
29,TTC29,NYD-SP14,ENSG00000137473,Tetratricopeptide repeat domain 29,4,146706638-146945882,Predicted intracellular proteins,Evidence at protein level,"HPA037006, HPA061473",Uncertain,,,,,Tissue enhanced,Group enriched,27,fallopian tube: 34.2;testis: 151.1,lung: 3.4,Cell line enhanced,,ASC TERT1: 3.4;hTERT-HME1: 1.2;U-266/70: 1.6;U-87 MG: 1.0
30,TRIML2,"FLJ25801, SPRYD6",ENSG00000179046,Tripartite motif family like 2,4,188091273-188109603,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA043838,Uncertain,,Approved,Plasma membrane<br>Cytosol,,Tissue enriched,Group enriched,26,placenta: 5.9;testis: 3.4,"cerebral cortex,lung: 0.1",Cell line enhanced,,A549: 30.5;BEWO: 17.7;hTCEpi: 15.4;NTERA-2: 34.0
31,TRPM1,"CSNB1C, LTRPC1, MLSN1",ENSG00000134160,Transient receptor potential cation channel subfamily M member 1,15,31001061-31161273,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA014779, HPA014785",Supported,,Uncertain,Nucleoplasm<br>Cytosol,,Tissue enriched,Group enriched,26,skin: 4.8;testis: 2.1,kidney: 0.1,Cell line enriched,91.0,SK-MEL-30: 9.1
32,ADGB,"C6orf103, CAPN16, dJ408K24.1, FLJ23121",ENSG00000118492,Androglobin,6,146598965-146815462,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036340, HPA036341",Enhanced,,Uncertain,Nucleoplasm<br>Mitochondria,,Not detected,Group enriched,25,fallopian tube: 14.9;testis: 58.5,lung: 1.4,Cell line enriched,25.0,HDLM-2: 13.3
33,CDY2A,CDY2,ENSG00000182415,Chromodomain Y-linked 2A,Y,18025787-18028597,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,24,epididymis: 1.3;testis: 3.5,all non-specific tissues: 0.0,Not detected,,
34,C4orf22,,ENSG00000197826,Chromosome 4 open reading frame 22,4,80335720-80963756,Predicted intracellular proteins,Evidence at transcript level,HPA043383,Approved,,Approved,Plasma membrane<br>Cytosol,,Not detected,Group enriched,23,fallopian tube: 30.6;testis: 47.6,lung: 1.7,Cell line enhanced,,A-431: 1.1;BJ: 1.4;SCLC-21H: 1.2
35,CLEC18C,MGC34761,ENSG00000157335,C-type lectin domain family 18 member C,16,70173322-70187361,Predicted secreted proteins,Evidence at transcript level,HPA048976,Uncertain,,,,,Tissue enriched,Group enriched,23,kidney: 11.4;testis: 3.6,duodenum: 0.3,Not detected,,
36,CXorf67,,ENSG00000187690,Chromosome X open reading frame 67,X,51406915-51408843,Predicted intracellular proteins,Evidence at protein level,"HPA004003, HPA006128",Enhanced,,Enhanced,Nucleoplasm,,Tissue enriched,Group enriched,21,placenta: 1.3;testis: 4.7,"cerebral cortex,epididymis,ovary,prostate,spleen: 0.1",Cell line enriched,63.0,U-2 OS: 34.0
37,NXF2,"CT39, TAPL-2",ENSG00000269405,Nuclear RNA export factor 2,X,102247161-102326719,Predicted intracellular proteins,Evidence at protein level,HPA002079,Uncertain,,,,,Not detected,Group enriched,21,epididymis: 18.6;testis: 23.3,fallopian tube: 0.9,Cell line enriched,38.0,U-266/84: 24.8
38,PFN3,,ENSG00000196570,Profilin 3,5,177400107-177400636,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,21,kidney: 1.0;testis: 3.2,all non-specific tissues: 0.0,Not detected,,
39,SLC24A5,"JSX, OCA6",ENSG00000188467,Solute carrier family 24 member 5,15,48120972-48142672,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,21,skin: 9.6;testis: 2.9,breast: 0.3,Cell line enriched,760.0,SK-MEL-30: 193.4
40,KRTAP21-2,KAP21.2,ENSG00000187026,Keratin associated protein 21-2,21,30746794-30747233,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,20,skin: 1.1;testis: 2.9,all non-specific tissues: 0.0,Cell line enriched,12.0,HEK93: 1.7
41,PNMA5,KIAA1934,ENSG00000198883,Paraneoplastic Ma antigen family member 5,X,152988824-152994127,Predicted intracellular proteins,Evidence at protein level,HPA044690,Enhanced,,,,"Colorectal cancer:2.25e-4 (unfavourable), Lung cancer:3.16e-4 (favourable)",Mixed,Group enriched,20,cerebral cortex: 8.1;testis: 16.3,"skin,spleen: 0.5",Group enriched,495.0,HMC-1: 311.7;U-266/70: 426.0;U-266/84: 249.2
42,PPP1R42,"dtr, LRRC67, TLLR",ENSG00000178125,Protein phosphatase 1 regulatory subunit 42,8,66964099-67056604,Predicted intracellular proteins,Evidence at transcript level,"HPA024313, HPA027983, HPA028628",Uncertain,,,,,Mixed,Group enriched,20,fallopian tube: 7.9;testis: 15.6,lung: 0.6,Not detected,,
43,RNF212B,C14orf164,ENSG00000215277,Ring finger protein 212B,14,23185316-23273477,Predicted intracellular proteins,Evidence at transcript level,HPA053574,Uncertain,,,,,Not detected,Group enriched,20,kidney: 27.7;testis: 10.4,thyroid gland: 0.9,Not detected,,
44,DNAAF1,"CILD13, FLJ25330, LRRC50, ODA7, swt",ENSG00000154099,Dynein axonemal assembly factor 1,16,84145287-84178767,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA041166, HPA074239",Enhanced,,Approved,Nuclear speckles<br>Plasma membrane<br>Cytosol,Endometrial cancer:2.14e-4 (favourable),Tissue enhanced,Group enriched,19,fallopian tube: 36.3;testis: 82.6,lung: 3.0,Cell line enhanced,,Hep G2: 1.4;Karpas-707: 3.6;PC-3: 1.4;U-266/70: 3.1;U-266/84: 2.0
45,OBP2A,"hOBPIIa, LCN13, OBP",ENSG00000122136,Odorant binding protein 2A,9,135546139-135549969,Predicted secreted proteins,Evidence at protein level,HPA055955,Uncertain,,,,,Tissue enriched,Group enriched,19,fallopian tube: 35.5;testis: 7.6,skin: 1.1,Group enriched,8.0,U-266/70: 1.0;U-266/84: 3.7
46,TBX22,"CLPA, CPX",ENSG00000122145,T-box 22,X,80014756-80031769,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Not detected,Group enriched,19,testis: 10.4;thyroid gland: 3.5,seminal vesicle: 0.3,Cell line enriched,6.0,HDLM-2: 1.6
47,DRC7,"C16orf50, CCDC135, CFAP50, DKFZp434I099, FAP50",ENSG00000159625,Dynein regulatory complex subunit 7,16,57694793-57731805,Predicted intracellular proteins,Evidence at protein level,,,,,,Endometrial cancer:3.61e-4 (favourable),Tissue enhanced,Group enriched,18,fallopian tube: 32.4;testis: 81.2,parathyroid gland: 3.2,Cell line enhanced,,Hep G2: 2.0
48,DSCR4,DCRB,ENSG00000184029,Down syndrome critical region 4,21,37951425-38121360,Predicted intracellular proteins,Evidence at transcript level,HPA018460,Uncertain,,,,,Tissue enriched,Group enriched,18,placenta: 2.0;testis: 1.4,all non-specific tissues: 0.0,Cell line enhanced,,BEWO: 5.8;K-562: 9.1;RPMI-8226: 3.0;U-266/70: 5.5;U-266/84: 3.9
49,IGLL1,"14.1, CD179B, IGL5, IGLL, IGVPB",ENSG00000128322,Immunoglobulin lambda like polypeptide 1,22,23573125-23580308,"CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA051134, HPA071406",Enhanced,,Approved,Endoplasmic reticulum,,Tissue enhanced,Group enriched,18,bone marrow: 44.2;testis: 15.8,tonsil: 1.6,Cell line enriched,39.0,REH: 687.9
50,SPRR2B,,ENSG00000196805,Small proline rich protein 2B,1,153070224-153070840,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Group enriched,18,esophagus: 30.3;skin: 17.1;testis: 8.2;tonsil: 14.1,ovary: 0.9,Not detected,,
51,C16orf71,"DKFZp686H2240, FLJ43261",ENSG00000166246,Chromosome 16 open reading frame 71,16,4734272-4749396,Predicted intracellular proteins,Evidence at protein level,HPA049468,Enhanced,,Uncertain,Nuclear speckles,Endometrial cancer:7.49e-4 (favourable),Mixed,Group enriched,17,fallopian tube: 35.8;testis: 113.1,lung: 4.3,Mixed,,
52,CCDC33,"CT61, FLJ32855",ENSG00000140481,Coiled-coil domain containing 33,15,74202705-74336472,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,17,fallopian tube: 75.4;testis: 22.5,lung: 2.8,Group enriched,5.0,CAPAN-2: 7.8;SCLC-21H: 5.8;SH-SY5Y: 6.3
53,C1orf189,,ENSG00000163263,Chromosome 1 open reading frame 189,1,154199372-154206333,Predicted intracellular proteins,Evidence at protein level,HPA045779,Uncertain,,,,,Tissue enhanced,Group enriched,16,fallopian tube: 127.5;testis: 69.2,"cervix, uterine: 6.0",Mixed,,
54,LEMD1,"CT50, LEMP-1",ENSG00000186007,LEM domain containing 1,1,205381378-205457091,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA045425,,,Approved,Nucleoli<br>Cytosol,"Ovarian cancer:1.26e-4 (favourable), Pancreatic cancer:1.70e-4 (unfavourable)",Tissue enhanced,Group enriched,16,epididymis: 18.1;testis: 71.4,fallopian tube: 2.7,Group enriched,6.0,CAPAN-2: 34.9;NTERA-2: 7.0
55,POTEI,POTE2beta,ENSG00000196834,POTE ankyrin domain family member I,2,130459455-130509666,Predicted intracellular proteins,Evidence at protein level,"HPA041264, HPA041271, HPA042822, HPA043260",Uncertain,,,,,Not detected,Group enriched,16,prostate: 17.4;testis: 10.3,breast: 0.8,Cell line enhanced,,AN3-CA: 2.5;BEWO: 3.2;K-562: 3.0;U-2 OS: 7.5
56,WFDC6,"C20orf171, dJ461P17.11, WAP6",ENSG00000243543,WAP four-disulfide core domain 6,20,45534196-45539495,Predicted secreted proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,16,epididymis: 323.7;testis: 83.8,fallopian tube: 12.5,Cell line enriched,7.0,U-87 MG: 2.6
57,ZMYND10,"BLU, CILD22",ENSG00000004838,Zinc finger MYND-type containing 10,3,50341110-50346852,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA035255,,,Approved,Plasma membrane<br>Cytosol,Renal cancer:6.75e-5 (favourable),Tissue enhanced,Group enriched,16,fallopian tube: 231.5;testis: 284.6,lung: 15.8,Cell line enhanced,,T-47d: 6.1;U-87 MG: 4.3
58,C1orf158,MGC35194,ENSG00000157330,Chromosome 1 open reading frame 158,1,12746215-12763699,Predicted intracellular proteins,Evidence at transcript level,HPA028396,,,Uncertain,Cytosol,,Group enriched,Group enriched,15,fallopian tube: 42.6;testis: 47.5,lung: 2.9,Not detected,,
59,FAM19A3,"TAFA-3, TAFA3",ENSG00000184599,"Family with sequence similarity 19 member A3, C-C motif chemokine like",1,112720419-112727235,Predicted secreted proteins,Evidence at transcript level,HPA055927,Approved,,,,Glioma:8.24e-4 (unfavourable),Mixed,Group enriched,15,adrenal gland: 19.9;testis: 8.7,epididymis: 0.9,Cell line enhanced,,BJ hTERT+: 3.7;HEL: 1.6;U-87 MG: 1.7
60,KRT25,KRT25A,ENSG00000204897,Keratin 25,17,40748021-40755332,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA053977, HPA058943",Enhanced,,Approved,Vesicles,,Not detected,Group enriched,15,breast: 3.6;testis: 1.6,smooth muscle: 0.1,Cell line enriched,5.0,RPTEC TERT1: 1.0
61,KRT33A,"Ha-3I, Krt1-3, KRTHA3A",ENSG00000006059,Keratin 33A,17,41346092-41350812,Predicted intracellular proteins,Evidence at protein level,HPA055194,Supported,,,,,Tissue enhanced,Group enriched,15,esophagus: 1.4;testis: 1.6,all non-specific tissues: 0.0,Cell line enhanced,,RT4: 1.1
62,MAGEA11,"CT1.11, MAGE-11, MAGE11, MAGEA-11, MGC10511",ENSG00000185247,MAGE family member A11,X,149688228-149717266,Predicted intracellular proteins,Evidence at protein level,HPA052687,,,Supported,Nucleoplasm<br>Nuclear bodies<br>Cytosol,,Mixed,Group enriched,15,epididymis: 25.8;testis: 6.9,placenta: 1.0,Cell line enhanced,,PC-3: 5.2;U-2 OS: 25.0;U-2197: 3.2
63,MDGA2,MAMDC1,ENSG00000139915,MAM domain containing glycosylphosphatidylinositol anchor 2,14,46839629-47674954,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA003084,Uncertain,,,,,Tissue enhanced,Group enriched,15,cerebral cortex: 6.2;testis: 6.9,skin: 0.4,Cell line enhanced,,AF22: 5.0;T-47d: 2.4;U-138 MG: 5.6;U-2 OS: 4.3;WM-115: 3.4
64,REG3G,"LPPM429, PAP1B, UNQ429",ENSG00000143954,Regenerating family member 3 gamma,2,79025686-79028505,Predicted secreted proteins,Evidence at protein level,"HPA047894, HPA048334, HPA060705",Uncertain,,Approved,Cytosol,,Tissue enriched,Group enriched,15,epididymis: 201.5;testis: 107.2,pancreas: 10.0,Not detected,,
65,TEKT4,MGC27019,ENSG00000163060,Tektin 4,2,94871433-94876829,Predicted intracellular proteins,Evidence at protein level,"HPA048600, HPA053929",Uncertain,,Uncertain,Intermediate filaments,Endometrial cancer:1.29e-4 (favourable),Tissue enriched,Group enriched,15,fallopian tube: 4.2;testis: 5.2,lung: 0.3,Not detected,,
66,UNC13C,"DKFZp547H074, Munc13-3",ENSG00000137766,Unc-13 homolog C,15,54012904-54633414,Predicted intracellular proteins,Evidence at protein level,HPA041516,Uncertain,,,,,Not detected,Group enriched,15,cerebral cortex: 17.4;testis: 15.3,"ovary,thyroid gland: 1.1",Group enriched,9.0,Karpas-707: 52.9;U-266/70: 74.2
67,AKAP14,AKAP28,ENSG00000186471,A-kinase anchoring protein 14,X,119895837-119920716,Predicted intracellular proteins,Evidence at protein level,HPA060999,Enhanced,,,,,Tissue enhanced,Group enriched,14,fallopian tube: 67.8;testis: 73.2,lung: 4.8,Cell line enhanced,,SCLC-21H: 2.9
68,CCDC96,FLJ90575,ENSG00000173013,Coiled-coil domain containing 96,4,7040849-7042939,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA047546,Enhanced,,,,"Renal cancer:3.80e-5 (favourable), Endometrial cancer:4.05e-4 (favourable), Pancreatic cancer:4.87e-4 (favourable)",Expressed in all,Group enriched,14,fallopian tube: 17.7;testis: 61.7,"cerebral cortex,lung: 2.7",Mixed,,
69,DAW1,"FLJ25955, ODA16, WDR69",ENSG00000123977,Dynein assembly factor with WD repeats 1,2,227871054-227924344,Predicted intracellular proteins,Evidence at protein level,HPA046118,Approved,,Approved,Nucleoplasm<br>Nuclear bodies,,Mixed,Group enriched,14,fallopian tube: 51.4;testis: 92.1,lung: 4.9,Cell line enhanced,,HUVEC TERT2: 18.4;U-2197: 40.4
70,DISP3,"KIAA1337, PTCHD2",ENSG00000204624,Dispatched RND transporter family member 3,1,11479166-11537584,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA054579,Uncertain,,Uncertain,Nucleoplasm<br>Cytosol,,Tissue enhanced,Group enriched,14,cerebral cortex: 8.6;testis: 4.3,"adrenal gland,prostate: 0.4",Cell line enhanced,,AF22: 4.8;NTERA-2: 2.1;SCLC-21H: 2.3;SH-SY5Y: 7.2
71,GGTLC1,"dJ831C21.1, dJ831C21.2, GGTLA3, GGTLA4",ENSG00000149435,Gamma-glutamyltransferase light chain 1,20,23985050-23988779,Predicted intracellular proteins,Evidence at protein level,"HPA045635, HPA047534",Uncertain,,,,,Tissue enriched,Group enriched,14,lung: 38.7;testis: 15.8,thyroid gland: 1.9,Not detected,,
72,GOLGA6B,,ENSG00000215186,Golgin A6 family member B,15,72654738-72666394,Predicted intracellular proteins,Evidence at protein level,"HPA044978, HPA050087",Supported,,,,,Not detected,Group enriched,14,liver: 1.9;testis: 5.3,cerebral cortex: 0.2,Not detected,,
73,HEMGN,"CT155, EDAG, NDR",ENSG00000136929,Hemogen,9,97926791-97944856,Predicted intracellular proteins,Evidence at protein level,"HPA019572, HPA019604, HPA019606",Enhanced,,,,,Not detected,Group enriched,14,bone marrow: 141.7;testis: 88.2,placenta: 8.1,Group enriched,7.0,HEL: 54.8;K-562: 247.2
74,NME8,"CILD6, NM23-H8, SPTRX2, TXNDC3",ENSG00000086288,NME/NM23 family member 8,7,37848597-37900401,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB016416, HPA019259",Supported,,,,,Mixed,Group enriched,14,bone marrow: 8.2;testis: 18.4,"appendix,spleen: 0.9",Cell line enhanced,,HMC-1: 1.1;NB-4: 1.2;NTERA-2: 1.7;THP-1: 1.1;U-937: 4.1
75,TP53TG3F,,ENSG00000278848,TP53 target 3 family member F,16,33459045-33462249,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,14,epididymis: 7.4;testis: 4.2,placenta: 0.4,Cell line enhanced,,HEL: 1.0
76,C1orf141,,ENSG00000203963,Chromosome 1 open reading frame 141,1,67092165-67231853,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,13,fallopian tube: 15.5;testis: 28.2,lung: 1.6,Cell line enriched,39.0,HEL: 13.1
77,CERS1,"LAG1, LASS1, UOG1",ENSG00000223802,Ceramide synthase 1,19,18868545-18896727,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA045724,Approved,,Approved,Endoplasmic reticulum,,Tissue enhanced,Group enriched,13,cerebral cortex: 136.3;testis: 28.0,skeletal muscle: 6.5,Cell line enhanced,,AN3-CA: 28.0;HEK93: 28.4
78,FABP12,,ENSG00000197416,Fatty acid binding protein 12,8,81524981-81531378,Predicted intracellular proteins,Evidence at protein level,HPA044041,Approved,,,,,Tissue enhanced,Group enriched,13,esophagus: 4.3;testis: 15.4,lung: 0.7,Not detected,,
79,FAM81B,FLJ25333,ENSG00000153347,Family with sequence similarity 81 member B,5,95391344-95450454,Predicted intracellular proteins,Evidence at protein level,HPA072554,Approved,,,,,Mixed,Group enriched,13,fallopian tube: 78.9;testis: 121.2,parathyroid gland: 7.5,Cell line enhanced,,CAPAN-2: 1.1
80,GSG1L2,,ENSG00000214978,GSG1 like 2,17,9802386-9822071,Predicted membrane proteins,Evidence at transcript level,HPA059428,Uncertain,,,,,Tissue enriched,Group enriched,13,cerebral cortex: 1.5;testis: 1.0,all non-specific tissues: 0.0,Not detected,,
81,LRRC46,MGC16309,ENSG00000141294,Leucine rich repeat containing 46,17,47831627-47837713,Predicted intracellular proteins,Evidence at protein level,"HPA021882, HPA074893",Enhanced,,Approved,Cytosol,Endometrial cancer:2.11e-4 (favourable),Tissue enhanced,Group enriched,13,fallopian tube: 120.7;testis: 55.6,lung: 6.5,Mixed,,
82,MAGEA10,"CT1.10, MAGE10, MGC10599",ENSG00000124260,MAGE family member A10,X,152133310-152138578,Predicted intracellular proteins,Evidence at protein level,"HPA003333, HPA070780",Approved,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,13,placenta: 13.5;testis: 4.8,skin: 0.7,Group enriched,9.0,PC-3: 7.4;SH-SY5Y: 5.3;U-266/84: 4.0;WM-115: 12.8
83,OTOA,"CT108, DFNB22",ENSG00000155719,Otoancorin,16,21678514-21760729,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA041405,Uncertain,,,,,Not detected,Group enriched,13,spleen: 2.6;testis: 6.0,epididymis: 0.3,Not detected,,
84,PNMA3,"MA3, MA5, MGC132756, MGC132758",ENSG00000183837,Paraneoplastic Ma antigen 3,X,153056409-153060467,Predicted intracellular proteins,Evidence at transcript level,HPA047920,Approved,,,,Endometrial cancer:4.14e-5 (unfavourable),Mixed,Group enriched,13,cerebral cortex: 15.4;epididymis: 45.4;testis: 12.3,fallopian tube: 1.8,Cell line enhanced,,NTERA-2: 3.2;SCLC-21H: 1.2
85,RPS4Y2,RPS4Y2P,ENSG00000280969,"Ribosomal protein S4, Y-linked 2",Y,20756164-20781032,"Predicted intracellular proteins, Ribosomal proteins",Evidence at protein level,HPA000857,Uncertain,,,,,Tissue enriched,Group enriched,13,prostate: 3.5;testis: 2.2,tonsil: 0.2,Cell line enriched,7.0,U-266/84: 1.3
86,SELENOV,SELV,ENSG00000186838,Selenoprotein V,19,39515113-39520686,Predicted intracellular proteins,Evidence at transcript level,HPA059274,Uncertain,,,,Thyroid cancer:7.43e-4 (unfavourable),Tissue enhanced,Group enriched,13,parathyroid gland: 1.8;testis: 5.5;thyroid gland: 2.1,cerebral cortex: 0.2,Not detected,,
87,TCTE1,"D6S46, DRC5, FAP155, MGC33600",ENSG00000146221,T-complex-associated-testis-expressed 1,6,44278743-44297688,Predicted intracellular proteins,Evidence at transcript level,HPA031739,,,Uncertain,Vesicles,,Tissue enhanced,Group enriched,13,fallopian tube: 23.1;testis: 35.3,lung: 2.2,Cell line enhanced,,SCLC-21H: 1.0
88,TRIM60,"FLJ35882, RNF129, RNF33",ENSG00000176979,Tripartite motif containing 60,4,165031953-165041744,Predicted intracellular proteins,Evidence at transcript level,"HPA035809, HPA035810, HPA061496",Uncertain,,,,,Tissue enriched,Group enriched,13,placenta: 2.1;testis: 2.7,skin: 0.1,Cell line enriched,17.0,BEWO: 13.5
89,ARMC3,"CT81, FLJ32827",ENSG00000165309,Armadillo repeat containing 3,10,22928024-23038523,Predicted intracellular proteins,Evidence at protein level,"HPA037823, HPA037824",Enhanced,,,,,Tissue enhanced,Group enriched,12,fallopian tube: 74.2;testis: 61.0,lung: 5.5,Cell line enriched,10.0,CAPAN-2: 5.3
90,C10orf90,"bA422P15.2, FATS, FLJ32938",ENSG00000154493,Chromosome 10 open reading frame 90,10,126424997-126670446,Predicted intracellular proteins,Evidence at protein level,"HPA038648, HPA057599",Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Tissue enriched,Group enriched,12,breast: 5.6;cerebral cortex: 15.3;salivary gland: 4.3;testis: 12.1,"adipose tissue,skin: 0.7",Group enriched,9.0,SK-MEL-30: 94.3;U-2197: 33.5;U-266/84: 18.9;U-87 MG: 36.2;WM-115: 29.4
91,CCDC65,"CFAP250, CILD27, DRC2, FAP250, FLJ35732, NYD-SP28",ENSG00000139537,Coiled-coil domain containing 65,12,48904110-48931840,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA038520, HPA057573",Uncertain,,Approved,Vesicles<br>Microtubule organizing center,,Mixed,Group enriched,12,fallopian tube: 42.8;testis: 67.9,lung: 4.4,Mixed,,
92,CFAP53,"CCDC11, FLJ32743",ENSG00000172361,Cilia and flagella associated protein 53,18,50227193-50266522,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA040595, HPA041069, HPA066142",Enhanced,,Approved,Midbody,Renal cancer:5.85e-4 (favourable),Mixed,Group enriched,12,fallopian tube: 44.6;testis: 127.0,epididymis: 6.9,Cell line enhanced,,hTERT-HME1: 3.5
93,CTNNA2,"CAP-R, CT114",ENSG00000066032,Catenin alpha 2,2,79185231-80648861,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB037175,Enhanced,,,,,Group enriched,Group enriched,12,cerebral cortex: 111.6;epididymis: 81.5;testis: 32.2,adrenal gland: 6.3,Cell line enhanced,,AF22: 7.0;Karpas-707: 5.9;NTERA-2: 6.7;SCLC-21H: 4.5;SH-SY5Y: 11.4
94,DDX25,GRTH,ENSG00000109832,DEAD-box helicase 25,11,125903348-125943702,"Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA020137,Enhanced,,,,,Tissue enhanced,Group enriched,12,cerebral cortex: 34.6;testis: 163.8,thyroid gland: 8.0,Cell line enhanced,,NTERA-2: 10.8;SCLC-21H: 10.2
95,DLGAP3,"DAP3, SAPAP3",ENSG00000116544,DLG associated protein 3,1,34865436-34929585,Predicted intracellular proteins,Evidence at protein level,HPA026445,Enhanced,,,,,Group enriched,Group enriched,12,cerebral cortex: 21.9;testis: 5.7,spleen: 1.1,Cell line enhanced,,Daudi: 5.7;NTERA-2: 4.2;SCLC-21H: 14.7
96,DNAAF3,"C19orf51, CILD2, FLJ36139, FLJ40069, PCD, PF22",ENSG00000167646,Dynein axonemal assembly factor 3,19,55158661-55166722,Predicted intracellular proteins,Evidence at protein level,HPA056220,,,Approved,Nuclear bodies<br>Mitochondria,Renal cancer:1.83e-5 (unfavourable),Mixed,Group enriched,12,fallopian tube: 69.1;testis: 67.9,lung: 5.9,Cell line enhanced,,HEK93: 24.3;HEL: 28.5;K-562: 22.5
97,FAM57B,DKFZP434I2117,ENSG00000149926,Family with sequence similarity 57 member B,16,30024427-30052978,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030837,Uncertain,,,,,Tissue enriched,Group enriched,12,cerebral cortex: 18.6;testis: 77.0,skeletal muscle: 3.9,Cell line enhanced,,NTERA-2: 16.7;SCLC-21H: 105.0;SH-SY5Y: 35.9
98,FSD1,"MGC3213, MIR1",ENSG00000105255,Fibronectin type III and SPRY domain containing 1,19,4304600-4323843,Predicted intracellular proteins,Evidence at protein level,HPA043141,Supported,,,,Endometrial cancer:1.61e-4 (unfavourable),Group enriched,Group enriched,12,cerebral cortex: 25.4;testis: 9.1,lymph node: 1.4,Cell line enhanced,,SCLC-21H: 65.0;SH-SY5Y: 60.9
99,HBZ,"HBZ-T1, HBZ1",ENSG00000130656,Hemoglobin subunit zeta,16,152687-154503,Predicted intracellular proteins,Evidence at protein level,HPA071726,Approved,,,,,Not detected,Group enriched,12,bone marrow: 2.3;placenta: 1.0;testis: 3.9,skin: 0.2,Cell line enriched,80.0,K-562: 2107.5
100,MEIG1,"bA2K17.3, SPATA39",ENSG00000197889,Meiosis/spermiogenesis associated 1,10,14959439-14988050,Predicted intracellular proteins,Evidence at transcript level,HPA044594,Uncertain,,,,,Mixed,Group enriched,12,fallopian tube: 6.7;testis: 13.0,cerebral cortex: 0.8,Cell line enhanced,,HDLM-2: 5.1
101,RGPD1,RGP1,ENSG00000187627,RANBP2-like and GRIP domain containing 1,2,86907953-87013981,Predicted intracellular proteins,Evidence at transcript level,"HPA049497, HPA051675, HPA067564",Uncertain,,Approved,Nuclear membrane<br>Vesicles,,Not detected,Group enriched,12,"cervix, uterine: 11.8;placenta: 9.0;testis: 24.5",parathyroid gland: 1.2,Cell line enhanced,,BEWO: 6.0;MOLT-4: 8.6;NTERA-2: 3.1
102,RP11-119J18.1,,ENSG00000250378,,5,135812667-135826584,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Group enriched,12,skin: 2.1;testis: 4.6,"breast,duodenum,esophagus,kidney: 0.2",Cell line enhanced,,HEL: 1.4;SK-MEL-30: 1.3
103,SH3GL3,"CNSA3, EEN-B2, HsT19371, SH3D2C, SH3P13",ENSG00000140600,"SH3 domain containing GRB2 like 3, endophilin A3",15,83447228-83618743,Predicted intracellular proteins,Evidence at protein level,HPA039381,Enhanced,,,,,Mixed,Group enriched,12,cerebral cortex: 29.9;testis: 38.5,lung: 2.9,Cell line enhanced,,HAP1: 30.3;HEK93: 13.3;K-562: 21.4;RH-30: 8.7
104,SLC30A3,ZNT3,ENSG00000115194,Solute carrier family 30 member 3,2,27253684-27275817,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA060505, HPA067637, CAB079044",Enhanced,Approved,Approved,Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol,,Mixed,Group enriched,12,cerebral cortex: 36.6;epididymis: 55.4;testis: 43.5,heart muscle: 3.6,Cell line enhanced,,HAP1: 10.6;Hep G2: 9.5;REH: 20.7;RH-30: 11.0
105,SPAG6,"CT141, pf16, Repro-SA-1",ENSG00000077327,Sperm associated antigen 6,10,22345445-22454224,Predicted intracellular proteins,Evidence at protein level,HPA038440,Enhanced,,,,,Mixed,Group enriched,12,fallopian tube: 77.7;testis: 172.6,lung: 10.7,Cell line enriched,22.0,U-937: 82.7
106,TTC16,FLJ32780,ENSG00000167094,Tetratricopeptide repeat domain 16,9,127716066-127731600,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,12,fallopian tube: 10.9;testis: 18.3,lung: 1.1,Not detected,,
107,ZIC3,"HTX, HTX1, ZNF203",ENSG00000156925,Zic family member 3,X,137566142-137577691,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA052936, HPA069523",Approved,,Supported,Nucleoplasm,,Tissue enriched,Group enriched,12,cerebral cortex: 1.6;testis: 1.3,"bone marrow,skin: 0.1",Group enriched,38.0,AF22: 39.4;NTERA-2: 44.7
108,ARMC4,"CILD23, DKFZP434P1735, FLJ10376, FLJ10817",ENSG00000169126,Armadillo repeat containing 4,10,27812164-27999048,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA037829,Enhanced,,,,,Mixed,Group enriched,11,fallopian tube: 28.9;testis: 40.2,prostate: 3.2,Cell line enhanced,,AF22: 6.0;RH-30: 14.9
109,C9orf24,"bA573M23.4, CBE1, MGC32921, MGC33614, NYD-SP22, SMRP1",ENSG00000164972,Chromosome 9 open reading frame 24,9,34379019-34397832,Predicted intracellular proteins,Evidence at protein level,HPA053008,Enhanced,,,,"Endometrial cancer:3.23e-5 (favourable), Pancreatic cancer:1.75e-4 (favourable)",Tissue enhanced,Group enriched,11,fallopian tube: 173.9;testis: 65.3,lung: 10.9,Not detected,,
110,DEUP1,"CCDC67, FLJ25393",ENSG00000165325,Deuterosome assembly protein 1,11,93329971-93438487,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010986,Uncertain,,,,,Not detected,Group enriched,11,fallopian tube: 7.6;testis: 29.8,thyroid gland: 1.6,Not detected,,
111,MAFA,"hMafA, RIPE3b1",ENSG00000182759,MAF bZIP transcription factor A,8,143419182-143430406,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Mixed,Group enriched,11,skeletal muscle: 8.6;testis: 2.5,placenta: 0.5,Cell line enhanced,,MCF7: 1.7;SCLC-21H: 3.7;T-47d: 2.8;U-2 OS: 2.1
112,MCF2,"ARHGEF21, DBL",ENSG00000101977,MCF.2 cell line derived transforming sequence,X,139581770-139708227,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,11,adrenal gland: 38.3;cerebral cortex: 8.7;epididymis: 15.0;ovary: 12.9;seminal vesicle: 24.0;testis: 34.6,prostate: 2.0,Cell line enriched,12.0,U-251 MG: 30.6
113,MYH7B,"dJ756N5.1, KIAA1512, MHC14, MYH14",ENSG00000078814,Myosin heavy chain 7B,20,34975403-35002437,Predicted intracellular proteins,Evidence at protein level,,,,,,Urothelial cancer:8.44e-5 (favourable),Mixed,Group enriched,11,heart muscle: 46.9;skeletal muscle: 55.9;testis: 11.7,"cerebral cortex,prostate: 3.3",Cell line enhanced,,U-138 MG: 1.5
114,PLPPR5,"LPPR5, PAP2, PAP2D, PRG5",ENSG00000117598,Phospholipid phosphatase related 5,1,98890245-99005032,Predicted membrane proteins,Evidence at transcript level,"HPA018072, HPA059085",Uncertain,,Approved,Plasma membrane<br>Cytosol,Renal cancer:6.22e-4 (unfavourable),Group enriched,Group enriched,11,cerebral cortex: 12.0;testis: 4.0,adrenal gland: 0.7,Group enriched,7.0,PC-3: 12.4;SH-SY5Y: 25.0
115,RDH8,"PRRDH, SDR28C2",ENSG00000080511,Retinol dehydrogenase 8 (all-trans),19,10013249-10022279,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Group enriched,Group enriched,11,kidney: 1.2;testis: 1.8,appendix: 0.1,Not detected,,
116,SULT6B1,,ENSG00000138068,Sulfotransferase family 6B member 1,2,37167820-37196598,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Group enriched,11,fallopian tube: 1.0;testis: 4.3,bone marrow: 0.2,Cell line enriched,6.0,WM-115: 2.2
117,TSGA10,"CEP4L, CT79",ENSG00000135951,Testis specific 10,2,98997261-99154964,Predicted intracellular proteins,Evidence at protein level,HPA036879,,,Approved,Cytosol,,Mixed,Group enriched,11,fallopian tube: 19.2;testis: 92.9,thyroid gland: 4.8,Cell line enhanced,,RPTEC TERT1: 3.1
118,ADIG,"MGC39724, RP5-1100H13.2, SMAF1",ENSG00000182035,Adipogenin,20,38581195-38588463,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA041124,Uncertain,,,,,Tissue enhanced,Group enriched,10,epididymis: 5.1;testis: 16.1;thyroid gland: 3.4,seminal vesicle: 0.8,Not detected,,
119,APOBEC4,"C1orf169, FLJ25691, MGC26594, RP1-127C7.4",ENSG00000173627,Apolipoprotein B mRNA editing enzyme catalytic polypeptide like 4,1,183646404-183653316,Predicted intracellular proteins,Evidence at transcript level,"HPA015636, HPA015637",Approved,,,,Endometrial cancer:2.65e-4 (favourable),Tissue enhanced,Group enriched,10,fallopian tube: 19.6;testis: 18.6,lung: 1.9,Not detected,,
120,C5orf49,LOC134121,ENSG00000215217,Chromosome 5 open reading frame 49,5,7830378-7851490,Predicted intracellular proteins,Evidence at protein level,HPA043759,Enhanced,,,,,Tissue enhanced,Group enriched,10,fallopian tube: 120.5;testis: 30.9,lung: 7.8,Not detected,,
121,CCDC81,"FLJ16339, FLJ23514",ENSG00000149201,Coiled-coil domain containing 81,11,86374736-86423109,Predicted intracellular proteins,Evidence at protein level,"HPA040745, HPA040827",Uncertain,,Uncertain,Plasma membrane,,Tissue enhanced,Group enriched,10,fallopian tube: 46.1;testis: 11.0,endometrium: 2.7,Cell line enhanced,,BJ: 2.9;HBF TERT88: 1.8
122,CFAP77,"C9orf171, FLJ46082",ENSG00000188523,Cilia and flagella associated protein 77,9,132410043-132573317,Predicted intracellular proteins,Evidence at protein level,"HPA021329, HPA024647, HPA061069",Enhanced,,Approved,Cytosol,Endometrial cancer:7.31e-4 (favourable),Tissue enhanced,Group enriched,10,fallopian tube: 48.8;testis: 22.9,lung: 3.4,Cell line enhanced,,SH-SY5Y: 2.1
123,CIB4,,ENSG00000157884,Calcium and integrin binding family member 4,2,26581202-26641368,Predicted intracellular proteins,Evidence at protein level,"HPA036130, HPA036131",Uncertain,,,,,Tissue enhanced,Group enriched,10,testis: 20.1;thyroid gland: 4.2,placenta: 1.1,Not detected,,
124,CLEC18B,,ENSG00000140839,C-type lectin domain family 18 member B,16,74408270-74421953,Predicted secreted proteins,Evidence at transcript level,HPA048976,Uncertain,,,,Glioma:1.55e-4 (unfavourable),Group enriched,Group enriched,10,kidney: 30.9;testis: 8.1,cerebral cortex: 2.0,Cell line enhanced,,AF22: 1.1;K-562: 2.7
125,CRB1,"LCA8, RP12",ENSG00000134376,"Crumbs 1, cell polarity complex component",1,197268204-197478455,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA061250, HPA063127",Approved,,Uncertain,Vesicles,,Tissue enriched,Group enriched,10,cerebral cortex: 12.2;testis: 5.0,ovary: 0.8,Cell line enriched,5.0,HeLa: 9.0
126,CSAG3,CSAG3A,ENSG00000268916,CSAG family member 3,X,152753921-152760222,Predicted intracellular proteins,Evidence at transcript level,HPA078264,,,Approved,Vesicles,,Mixed,Group enriched,10,lymph node: 1.7;skin: 1.2;spleen: 1.9;testis: 4.2,"adipose tissue,lung,placenta: 0.2",Cell line enhanced,,HDLM-2: 23.7;HMC-1: 22.9;SH-SY5Y: 35.8;SK-BR-3: 23.6;U-2 OS: 25.4;U-266/70: 61.5;U-266/84: 30.6
127,DLGAP2,DAP-2,ENSG00000198010,DLG associated protein 2,8,737596-1708474,"Nuclear receptors, Predicted intracellular proteins",Evidence at protein level,HPA030320,Uncertain,,,,,Not detected,Group enriched,10,cerebral cortex: 2.0;testis: 6.1,thyroid gland: 0.4,Not detected,,
128,DNAI1,"CILD1, DIC1, PCD",ENSG00000122735,Dynein axonemal intermediate chain 1,9,34457414-34520989,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021649, HPA021843",Enhanced,,,,,Tissue enhanced,Group enriched,10,fallopian tube: 54.3;testis: 61.2,lung: 5.6,Cell line enhanced,,BEWO: 1.9;HDLM-2: 1.3
129,DRC1,"C2orf39, CCDC164, CILD21, FLJ32660, MGC16372",ENSG00000157856,Dynein regulatory complex subunit 1,2,26401916-26456711,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,10,fallopian tube: 62.4;testis: 36.8,lung: 4.7,Not detected,,
130,EFCAB10,,ENSG00000185055,EF-hand calcium binding domain 10,7,105565120-105600875,Predicted intracellular proteins,Evidence at transcript level,HPA019751,Uncertain,,,,,Mixed,Group enriched,10,fallopian tube: 44.0;testis: 39.9,lung: 4.3,Mixed,,
131,ODF3L2,"C19orf19, FLJ40059",ENSG00000181781,Outer dense fiber of sperm tails 3 like 2,19,463346-474983,Predicted intracellular proteins,Evidence at protein level,HPA067973,Uncertain,,,,,Not detected,Group enriched,10,skeletal muscle: 2.7;testis: 7.6,spleen: 0.5,Not detected,,
132,SLC9C1,"NHE, SLC9A10",ENSG00000172139,Solute carrier family 9 member C1,3,112140887-112294258,"Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Not detected,Group enriched,10,skin: 2.9;testis: 14.1,thyroid gland: 0.8,Not detected,,
133,SPAG8,"BS-84, CT142, HSD-1, hSMP-1, SPAG3",ENSG00000137098,Sperm associated antigen 8,9,35808045-35812272,Predicted intracellular proteins,Evidence at protein level,HPA068012,Enhanced,,,,Endometrial cancer:2.15e-4 (favourable),Mixed,Group enriched,10,fallopian tube: 28.6;testis: 16.3,thyroid gland: 2.2,Not detected,,
134,SRRM3,FLJ37078,ENSG00000177679,Serine/arginine repetitive matrix 3,7,76201900-76287288,Predicted intracellular proteins,Evidence at protein level,HPA019337,Uncertain,,Approved,Plasma membrane<br>Intermediate filaments<br>Microtubules,,Mixed,Group enriched,10,adrenal gland: 2.7;cerebral cortex: 8.5;testis: 1.8,stomach: 0.4,Group enriched,12.0,SCLC-21H: 12.8;SH-SY5Y: 8.5
135,TEX11,"TGC1, TSGA3",ENSG00000120498,Testis expressed 11,X,70528940-70908731,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA002950,Approved,,,,,Tissue enhanced,Group enriched,10,pancreas: 12.3;testis: 21.1,rectum: 1.7,Not detected,,
136,TSNAXIP1,TXI1,ENSG00000102904,Translin associated factor X interacting protein 1,16,67806765-67832148,Predicted intracellular proteins,Evidence at protein level,HPA053516,,,Approved,Nucleus<br>Cytosol,Endometrial cancer:2.22e-4 (favourable),Mixed,Group enriched,10,fallopian tube: 15.6;testis: 39.9,parathyroid gland: 2.7,Cell line enhanced,,AN3-CA: 2.8
137,VSIG1,MGC44287,ENSG00000101842,V-set and immunoglobulin domain containing 1,X,108044970-108079184,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA001445, HPA036310, HPA036311",Enhanced,,Approved,Vesicles<br>Cytosol,,Group enriched,Group enriched,10,stomach: 185.7;testis: 91.1,gallbladder: 14.3,Cell line enhanced,,HBEC3-KT: 2.5;HUVEC TERT2: 5.9;PC-3: 2.2
138,ZBBX,FLJ23049,ENSG00000169064,Zinc finger B-box domain containing,3,167240287-167381346,Predicted intracellular proteins,Evidence at protein level,"HPA036327, HPA036328",Enhanced,,,,,Tissue enhanced,Group enriched,10,fallopian tube: 38.1;testis: 67.6,lung: 5.5,Not detected,,
139,C11orf97,LINC01171,ENSG00000257057,Chromosome 11 open reading frame 97,11,94512432-94532123,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,9,fallopian tube: 28.3;testis: 12.6,lung: 2.3,Not detected,,
140,CCDC150,FLJ39660,ENSG00000144395,Coiled-coil domain containing 150,2,196639554-196763490,Predicted intracellular proteins,Evidence at protein level,"HPA043968, HPA048104",Uncertain,,Approved,Nucleoplasm,,Mixed,Group enriched,9,kidney: 2.6;testis: 8.8,liver: 0.6,Cell line enhanced,,SCLC-21H: 5.2
141,CCNB3,,ENSG00000147082,Cyclin B3,X,50202713-50351910,Predicted intracellular proteins,Evidence at protein level,HPA000496,Enhanced,,Supported,Nuclear speckles,,Not detected,Group enriched,9,epididymis: 5.8;testis: 7.9,cerebral cortex: 0.7,Cell line enhanced,,CAPAN-2: 1.5
142,CERS3,"LASS3, MGC27091",ENSG00000154227,Ceramide synthase 3,15,100400395-100544995,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA006092, HPA024356",Approved,,Approved,Nucleoplasm,,Tissue enhanced,Group enriched,9,esophagus: 48.1;skin: 60.5;testis: 32.3;tonsil: 14.3,breast: 4.3,Cell line enriched,6.0,hTCEpi: 47.1
143,CFAP52,"FLJ37528, WDR16, WDRPUH",ENSG00000166596,Cilia and flagella associated protein 52,17,9576627-9643459,Predicted intracellular proteins,Evidence at protein level,HPA023247,Enhanced,,,,,Mixed,Group enriched,9,fallopian tube: 91.8;testis: 22.0,lung: 6.6,Cell line enhanced,,CAPAN-2: 1.5;MCF7: 1.6;REH: 1.3;T-47d: 1.1
144,CNGA4,"CNCA2, CNG5, CNGB2, OCNC2, OCNCb",ENSG00000132259,Cyclic nucleotide gated channel alpha 4,11,6234765-6244429,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,Endometrial cancer:1.48e-4 (favourable),Tissue enriched,Group enriched,9,fallopian tube: 27.9;testis: 10.5,lung: 2.1,Not detected,,
145,DOC2A,,ENSG00000149927,Double C2 domain alpha,16,30005509-30023270,Predicted intracellular proteins,Evidence at protein level,HPA065676,,,Uncertain,Nucleus<br>Nucleoli<br>Cell Junctions,,Tissue enhanced,Group enriched,9,cerebral cortex: 69.7;testis: 21.0,ovary: 5.2,Cell line enhanced,,BEWO: 12.9;SCLC-21H: 42.7;U-937: 14.1
146,ELAVL4,"HUD, PNEM",ENSG00000162374,ELAV like RNA binding protein 4,1,50048014-50203786,Predicted intracellular proteins,Evidence at protein level,"CAB004442, HPA043047",Enhanced,,Approved,Nucleoplasm<br>Vesicles,,Group enriched,Group enriched,9,adrenal gland: 10.7;cerebral cortex: 53.3;testis: 10.9,appendix: 2.9,Cell line enriched,21.0,SH-SY5Y: 131.1
147,FSHR,"FSHRO, LGR1, ODG1",ENSG00000170820,Follicle stimulating hormone receptor,2,48962157-49154537,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,,Not detected,Group enriched,9,ovary: 2.5;testis: 4.3,gallbladder: 0.3,Not detected,,
148,KIAA1107,,ENSG00000069712,KIAA1107,1,92166985-92184723,Predicted intracellular proteins,Evidence at protein level,HPA024216,Supported,,,,,Mixed,Group enriched,9,cerebral cortex: 45.9;testis: 10.7,"adrenal gland,epididymis: 3.2",Mixed,,
149,LOXHD1,"DFNB77, FLJ32670, LH2D1",ENSG00000167210,Lipoxygenase homology domains 1,18,46476972-46657033,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,9,epididymis: 8.3;testis: 41.3,fallopian tube: 2.6,Not detected,,
150,LRRC71,"C1orf92, FLJ32884",ENSG00000160838,Leucine rich repeat containing 71,1,156920650-156933094,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Group enriched,9,fallopian tube: 20.1;testis: 22.2,lung: 2.3,Cell line enhanced,,HBEC3-KT: 2.6;PC-3: 1.5;TIME: 1.2
151,MAK,"dJ417M14.2, RP62",ENSG00000111837,Male germ cell associated kinase,6,10762723-10838555,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,9,fallopian tube: 9.7;parathyroid gland: 10.2;testis: 20.4,lung: 1.4,Cell line enhanced,,HDLM-2: 1.4
152,PENK,,ENSG00000181195,Proenkephalin,8,56436674-56446734,"Plasma proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA013138, CAB016390",Enhanced,,,,,Tissue enhanced,Group enriched,9,adrenal gland: 566.0;testis: 208.0,prostate: 41.3,Cell line enhanced,,ASC diff: 10.8;ASC TERT1: 6.5;BJ: 7.7;THP-1: 5.8
153,PROK1,"EGVEGF, PK1, PRK1",ENSG00000143125,Prokineticin 1,1,110451200-110457354,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,9,ovary: 239.3;placenta: 75.8;testis: 119.4,seminal vesicle: 15.2,Cell line enriched,9.0,ASC diff: 16.3
154,RIIAD1,"C1orf230, FLJ36032, NCRNA00166",ENSG00000178796,Regulatory subunit of type II PKA R-subunit (RIIa) domain containing 1,1,151710433-151729805,Predicted intracellular proteins,Evidence at protein level,HPA045703,Enhanced,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:5.46e-4 (favourable),Tissue enhanced,Group enriched,9,fallopian tube: 70.7;testis: 22.5,cerebral cortex: 5.4,Group enriched,9.0,CACO-2: 3.6;SCLC-21H: 2.7;SH-SY5Y: 4.8;SK-BR-3: 5.4
155,TEKT2,TEKTB1,ENSG00000092850,Tektin 2,1,36084075-36088275,Predicted intracellular proteins,Evidence at protein level,"HPA027248, HPA027461",Approved,,Uncertain,Microtubules,Renal cancer:1.98e-4 (favourable),Tissue enhanced,Group enriched,9,fallopian tube: 97.8;testis: 63.3,lung: 8.8,Cell line enriched,5.0,NB-4: 23.2
156,TMEM130,"DKFZp761L1417, FLJ42643",ENSG00000166448,Transmembrane protein 130,7,98846488-98870771,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012928,Uncertain,,Supported,Golgi apparatus,Lung cancer:7.84e-4 (favourable),Tissue enhanced,Group enriched,9,adrenal gland: 49.1;cerebral cortex: 183.0;testis: 70.7,epididymis: 11.5,Cell line enhanced,,BJ hTERT+: 5.4;EFO-21: 6.0;NTERA-2: 3.8;SH-SY5Y: 8.3
157,VWA3B,"DKFZp686F2227, MGC26733",ENSG00000168658,Von Willebrand factor A domain containing 3B,2,98087116-98313299,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA036700, HPA036701",Approved,,Approved,Nucleus,,Tissue enhanced,Group enriched,9,fallopian tube: 41.2;testis: 36.2,lung: 4.3,Not detected,,
158,ZFR2,KIAA1086,ENSG00000105278,Zinc finger RNA binding protein 2,19,3804024-3869032,Predicted intracellular proteins,Evidence at protein level,"HPA043275, HPA055678",Uncertain,,Uncertain,Nucleoplasm,,Tissue enhanced,Group enriched,9,adrenal gland: 3.8;cerebral cortex: 12.7;testis: 19.0,fallopian tube: 1.3,Group enriched,12.0,HMC-1: 24.1;NTERA-2: 47.6;SiHa: 15.2
159,AQP5,,ENSG00000161798,Aquaporin 5,12,49961870-49965681,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA065008,Enhanced,,Approved,Plasma membrane,Head and neck cancer:1.75e-5 (favourable),Tissue enhanced,Group enriched,8,salivary gland: 255.6;stomach: 53.3;testis: 176.4,breast: 21.1,Group enriched,9.0,CAPAN-2: 7.6;REH: 9.2
160,ASB18,,ENSG00000182177,Ankyrin repeat and SOCS box containing 18,2,236194872-236264409,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA068447,Approved,,,,,Not detected,Group enriched,8,heart muscle: 4.3;skeletal muscle: 3.6;testis: 1.0,cerebral cortex: 0.4,Not detected,,
161,C5orf46,"MGC23985, SSSP1",ENSG00000178776,Chromosome 5 open reading frame 46,5,147880726-147906538,Predicted secreted proteins,Evidence at transcript level,HPA058999,,,Approved,Nuclear speckles<br>Mitochondria,"Renal cancer:1.75e-9 (unfavourable), Cervical cancer:3.98e-4 (unfavourable)",Tissue enhanced,Group enriched,8,breast: 17.6;salivary gland: 77.2;skin: 62.4;testis: 19.9,heart muscle: 5.8,Cell line enhanced,,PC-3: 83.2;SiHa: 21.5;U-2 OS: 59.9;U-251 MG: 19.3
162,C9orf135,,ENSG00000204711,Chromosome 9 open reading frame 135,9,69820793-69906232,Predicted intracellular proteins,Evidence at protein level,"HPA021261, HPA021325",Uncertain,,,,,Tissue enriched,Group enriched,8,fallopian tube: 55.2;testis: 24.3,parathyroid gland: 5.1,Group enriched,9.0,HAP1: 11.5;NTERA-2: 29.5
163,CACNA1B,"CACNL1A5, CACNN, Cav2.2",ENSG00000148408,Calcium voltage-gated channel subunit alpha1 B,9,137877789-138124624,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA044347,Uncertain,,,,,Tissue enhanced,Group enriched,8,adrenal gland: 3.7;cerebral cortex: 14.8;fallopian tube: 4.9;testis: 7.6,prostate: 0.9,Cell line enriched,6.0,SCLC-21H: 23.0
164,CFAP57,"FLJ32000, WDR65",ENSG00000243710,Cilia and flagella associated protein 57,1,43172149-43254358,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA002736, HPA028623",Enhanced,,Approved,Cytosol,Endometrial cancer:6.02e-4 (favourable),Mixed,Group enriched,8,fallopian tube: 35.6;testis: 27.7,lung: 3.7,Cell line enhanced,,HaCaT: 2.5
165,CFAP99,,ENSG00000206113,Cilia and flagella associated protein 99,4,2418974-2462942,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,8,fallopian tube: 7.0;testis: 11.3,adrenal gland: 1.0,Not detected,,
166,CTAG2,"CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803",ENSG00000126890,Cancer/testis antigen 2,X,154651972-154653579,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA071467,Enhanced,,,,Liver cancer:2.35e-4 (unfavourable),Mixed,Group enriched,8,fallopian tube: 2.6;heart muscle: 3.2;placenta: 3.6;skeletal muscle: 1.2;testis: 6.0,pancreas: 0.4,Group enriched,29.0,K-562: 126.4;RPMI-8226: 215.0;SK-BR-3: 146.5;U-266/84: 251.9
167,CTC-479C5.6,,ENSG00000263201,,16,68013436-68015911,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,8,placenta: 1.2;testis: 3.1,bone marrow: 0.2,Not detected,,
168,CTXN2,,ENSG00000233932,Cortexin 2,15,48191539-48203756,Predicted membrane proteins,Evidence at transcript level,HPA053168,Uncertain,,,,,Not detected,Group enriched,8,cerebral cortex: 1.9;testis: 1.5,fallopian tube: 0.2,Not detected,,
169,CYP2F1,CYP2F,ENSG00000197446,Cytochrome P450 family 2 subfamily F member 1,19,41114432-41128366,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,8,lung: 2.4;testis: 1.9,"bone marrow,esophagus,tonsil: 0.2",Group enriched,16.0,HMC-1: 4.7;K-562: 4.5
170,DNAH2,"DNHD3, FLJ46675, KIAA1503",ENSG00000183914,Dynein axonemal heavy chain 2,17,7717354-7833744,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA067103,Enhanced,,Approved,Microtubules,,Mixed,Group enriched,8,fallopian tube: 20.9;parathyroid gland: 28.4;testis: 10.9,placenta: 2.5,Cell line enhanced,,A-431: 2.2;CACO-2: 3.2;CAPAN-2: 2.1;SCLC-21H: 2.7;SiHa: 2.4
171,DNAI2,"CILD9, DIC2",ENSG00000171595,Dynein axonemal intermediate chain 2,17,74274247-74314884,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB006245, HPA050565",Enhanced,,,,,Tissue enhanced,Group enriched,8,fallopian tube: 48.0;testis: 27.7,lung: 4.6,Cell line enhanced,,HMC-1: 1.6
172,DPPA4,FLJ10713,ENSG00000121570,Developmental pluripotency associated 4,3,109326141-109337572,Predicted intracellular proteins,Evidence at protein level,"CAB020678, HPA035249, HPA035250",Enhanced,,Supported,Nucleus<br>Nucleoli,,Tissue enriched,Group enriched,8,bone marrow: 2.8;placenta: 3.0;testis: 7.7,"lung,lymph node: 0.5",Cell line enhanced,,AF22: 42.6;HAP1: 92.5;NTERA-2: 327.0
173,DPYSL5,"CRAM, CRMP-5, CRMP5, Ulip6",ENSG00000157851,Dihydropyrimidinase like 5,2,26847747-26950351,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034544, HPA072387",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Group enriched,Group enriched,8,cerebral cortex: 31.3;testis: 10.0,adrenal gland: 2.5,Cell line enhanced,,AF22: 139.1;HAP1: 122.4;SCLC-21H: 196.8;SH-SY5Y: 105.0
174,DRICH1,C22orf43,ENSG00000189269,Aspartate rich 1,22,23608452-23632321,Predicted intracellular proteins,Evidence at protein level,HPA020446,,,Approved,Nucleus<br>Nucleoli,,Mixed,Group enriched,8,epididymis: 20.8;parathyroid gland: 23.9;testis: 81.2,endometrium: 5.4,Cell line enhanced,,CACO-2: 9.2
175,DYNLRB2,"DNCL2B, DNLC2B, ROBLD2",ENSG00000168589,Dynein light chain roadblock-type 2,16,80540734-80550760,Predicted intracellular proteins,Evidence at protein level,,,,,,Endometrial cancer:3.91e-5 (favourable),Mixed,Group enriched,8,fallopian tube: 134.8;testis: 325.7,epididymis: 27.5,Cell line enhanced,,MCF7: 4.4;RPTEC TERT1: 2.8;SCLC-21H: 2.2
176,ERFE,"C1QTNF15, CTRP15, FAM132B, FLJ37034",ENSG00000178752,Erythroferrone,2,238158982-238168900,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA077259,,,Approved,Endoplasmic reticulum<br>Microtubule organizing center,"Renal cancer:2.46e-4 (unfavourable), Endometrial cancer:3.75e-4 (unfavourable)",Tissue enhanced,Group enriched,8,testis: 17.2;thyroid gland: 40.6,appendix: 3.4,Cell line enhanced,,RH-30: 25.5
177,FAM135B,C8ORFK32,ENSG00000147724,Family with sequence similarity 135 member B,8,138130023-138496822,Predicted intracellular proteins,Evidence at transcript level,"HPA023911, HPA023950, HPA024815",Uncertain,,Approved,Nucleoplasm<br>Nuclear membrane,,Tissue enhanced,Group enriched,8,adrenal gland: 3.6;cerebral cortex: 8.3;testis: 7.3,colon: 0.8,Cell line enriched,11.0,RH-30: 8.5
178,HTR7,5-HT7,ENSG00000148680,5-hydroxytryptamine receptor 7,10,90740823-90857698,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,"CAB022708, HPA073617",Approved,,Supported,Nuclear speckles<br>Plasma membrane<br>Cytosol,,Group enriched,Group enriched,8,parathyroid gland: 44.8;testis: 16.1,urinary bladder: 3.8,Cell line enhanced,,hTERT-HME1: 25.8;LHCN-M2: 11.4;WM-115: 12.9
179,LRGUK,"CFAP246, FLJ32786",ENSG00000155530,Leucine rich repeats and guanylate kinase domain containing,7,134127299-134264591,Predicted intracellular proteins,Evidence at protein level,"HPA029505, HPA029506",Uncertain,,,,,Mixed,Group enriched,8,epididymis: 1.7;fallopian tube: 5.4;testis: 8.4,"lung,thyroid gland: 0.6",Cell line enhanced,,NTERA-2: 1.4;SH-SY5Y: 1.3;SK-MEL-30: 1.4
180,LRRC18,"MGC34773, UNQ933, UNQ9338, VKGE9338",ENSG00000165383,Leucine rich repeat containing 18,10,48909483-48914232,Predicted intracellular proteins,Evidence at protein level,HPA039256,Enhanced,,,,,Tissue enhanced,Group enriched,8,fallopian tube: 12.1;testis: 25.3,lung: 2.3,Not detected,,
181,LRRC34,MGC27085,ENSG00000171757,Leucine rich repeat containing 34,3,169793428-169812986,Predicted intracellular proteins,Evidence at protein level,HPA035747,Approved,,Approved,Cell Junctions<br>Microtubules<br>Cytokinetic bridge,,Mixed,Group enriched,8,fallopian tube: 12.2;testis: 26.8,cerebral cortex: 2.2,Cell line enhanced,,HEL: 7.6;HL-60: 7.2;NTERA-2: 8.7
182,MAP3K19,"FLJ23074, RCK, YSK4",ENSG00000176601,Mitogen-activated protein kinase kinase kinase 19,2,134964491-135047468,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA011388,,,Uncertain,Cytosol,,Tissue enhanced,Group enriched,8,fallopian tube: 28.5;testis: 7.8,lung: 2.2,Not detected,,
183,MCF2L2,"ARHGEF22, KIAA0861",ENSG00000053524,MCF.2 cell line derived transforming sequence-like 2,3,183178043-183428778,"Disease related genes, Predicted intracellular proteins",Evidence at transcript level,"HPA038946, HPA038947",Uncertain,,Approved,Plasma membrane<br>Cytosol,,Not detected,Group enriched,8,adrenal gland: 10.2;cerebral cortex: 17.2;parathyroid gland: 7.7;spleen: 3.5;testis: 4.7,prostate: 1.0,Cell line enhanced,,HDLM-2: 5.5;Karpas-707: 3.6;REH: 3.1
184,MROH2A,HEATR7B1,ENSG00000185038,Maestro heat like repeat family member 2A,2,233775679-233833423,Predicted intracellular proteins,Evidence at transcript level,HPA052107,Uncertain,,Uncertain,Cytosol,,Tissue enhanced,Group enriched,8,testis: 3.2;thyroid gland: 2.7,"liver,stomach: 0.3",Cell line enriched,8.0,RT4: 4.8
185,NEK5,,ENSG00000197168,NIMA related kinase 5,13,52033611-52129078,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035565, HPA041399",Enhanced,,,,,Mixed,Group enriched,8,fallopian tube: 12.2;testis: 18.7,lung: 1.9,Cell line enhanced,,T-47d: 1.0
186,NR0B1,"AHC, AHCH, DAX1, DSS",ENSG00000169297,Nuclear receptor subfamily 0 group B member 1,X,30304206-30309598,"Cancer-related genes, Disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA061948, HPA067207",,,Supported,Nuclear speckles<br>Vesicles<br>Microtubule organizing center,,Tissue enhanced,Group enriched,8,adrenal gland: 27.8;testis: 35.0,ovary: 4.1,Cell line enhanced,,A549: 51.8;RT4: 14.5;U-87 MG: 7.9
187,PAX3,"HUP2, WS1",ENSG00000135903,Paired box 3,2,222199888-222298996,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA063659, HPA069000",Approved,,Supported,Nucleoplasm,,Tissue enriched,Group enriched,8,breast: 1.2;skeletal muscle: 1.1;skin: 3.2;testis: 2.4,prostate: 0.2,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 9.6;BJ hTERT+ SV40 Large T+ RasG12V: 11.6;RH-30: 16.2;SK-MEL-30: 24.6
188,PIH1D3,"CXorf41, MGC35261, NYSAR97",ENSG00000080572,PIH1 domain containing 3,X,107206632-107244243,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA072496,Enhanced,,,,,Tissue enhanced,Group enriched,8,fallopian tube: 17.4;testis: 13.8,lung: 1.9,Not detected,,
189,PRAME,"CT130, MAPE",ENSG00000185686,Preferentially expressed antigen in melanoma,22,22547701-22559361,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA045153,Enhanced,,,,"Renal cancer:7.48e-9 (unfavourable), Head and neck cancer:3.41e-4 (unfavourable)",Group enriched,Group enriched,8,epididymis: 17.1;testis: 80.5,endometrium: 6.3,Cell line enhanced,,HMC-1: 154.1;K-562: 872.4;SH-SY5Y: 199.7;U-2 OS: 171.5
190,PXDNL,"FLJ25471, PMR1",ENSG00000147485,Peroxidasin like,8,51319578-51809445,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA007919,,,Approved,Nucleoplasm<br>Cytosol,Breast cancer:3.27e-5 (unfavourable),Mixed,Group enriched,8,epididymis: 11.5;heart muscle: 24.1;testis: 9.0,adipose tissue: 1.8,Group enriched,7.0,AF22: 7.6;Daudi: 4.2;SH-SY5Y: 6.5
191,RASGEF1C,FLJ35841,ENSG00000146090,RasGEF domain family member 1C,5,180100791-180209153,Predicted intracellular proteins,Evidence at transcript level,HPA028242,Uncertain,,Approved,Mitochondria,,Tissue enhanced,Group enriched,8,cerebral cortex: 16.4;testis: 6.1,seminal vesicle: 1.3,Cell line enhanced,,BEWO: 2.2;MCF7: 1.9;SCLC-21H: 9.1;U-2 OS: 2.5
192,RGS7,,ENSG00000182901,Regulator of G-protein signaling 7,1,240775515-241357230,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB017561,Enhanced,,Enhanced,Cytosol,,Tissue enhanced,Group enriched,8,adrenal gland: 10.7;cerebral cortex: 46.4;testis: 10.9,stomach: 2.9,Cell line enhanced,,U-2 OS: 6.8
193,RIBC2,"C22orf11, DKFZp566F0546, FLJ25720",ENSG00000128408,RIB43A domain with coiled-coils 2,22,45413691-45432496,Predicted intracellular proteins,Evidence at transcript level,HPA003210,Uncertain,,,,Cervical cancer:7.08e-8 (favourable),Mixed,Group enriched,8,fallopian tube: 15.9;testis: 37.3,parathyroid gland: 3.1,Cell line enhanced,,SiHa: 13.9
194,RSPH10B,,ENSG00000155026,Radial spoke head 10 homolog B,7,5925550-5970683,Predicted intracellular proteins,Evidence at protein level,HPA049182,Supported,,,,,Not detected,Group enriched,8,fallopian tube: 13.4;testis: 35.8,parathyroid gland: 3.0,Not detected,,
195,SAG,"ARRESTIN, RP47",ENSG00000130561,S-antigen visual arrestin,2,233307816-233347055,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA004946,Supported,,,,,Not detected,Group enriched,8,epididymis: 1.1;testis: 1.9,endometrium: 0.1,Not detected,,
196,SEC14L4,"dJ130H16.5, TAP3",ENSG00000133488,SEC14 like lipid binding 4,22,30488913-30505711,Predicted intracellular proteins,Evidence at protein level,HPA069748,,,Approved,Centrosome,,Tissue enhanced,Group enriched,8,bone marrow: 5.0;liver: 10.3;lung: 6.9;parathyroid gland: 10.5;testis: 7.1,adrenal gland: 0.9,Cell line enhanced,,A549: 6.7;BEWO: 36.9;SiHa: 9.8
197,SLC22A16,"CT2, FLIPT2, OAT6, OKB1",ENSG00000004809,Solute carrier family 22 member 16,6,110424687-110476641,Predicted membrane proteins,Evidence at protein level,HPA036902,Uncertain,,,,,Tissue enriched,Group enriched,8,bone marrow: 12.9;parathyroid gland: 16.3;testis: 38.6,smooth muscle: 2.7,Group enriched,16.0,NB-4: 10.5;REH: 14.0;THP-1: 35.6;U-937: 24.4
198,SOX1,,ENSG00000182968,SRY-box 1,13,112067647-112070488,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Group enriched,Group enriched,8,cerebral cortex: 3.6;testis: 1.5,skin: 0.3,Group enriched,6.0,AF22: 44.0;SCLC-21H: 10.1
199,SYCP2,SCP2,ENSG00000196074,Synaptonemal complex protein 2,20,59863563-59933655,Predicted intracellular proteins,Evidence at protein level,"HPA062401, HPA065613",,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Group enriched,Group enriched,8,breast: 17.7;testis: 76.9,prostate: 6.0,Cell line enhanced,,MOLT-4: 43.5;SiHa: 97.9;T-47d: 77.3
200,SYT16,"CHR14SYT, Strep14, SYT14L, yt14r",ENSG00000139973,Synaptotagmin 16,14,61811974-62112550,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA004199, HPA076871",Uncertain,,Approved,Cytosol,,Mixed,Group enriched,8,cerebral cortex: 18.0;prostate: 3.6;testis: 6.9,stomach: 1.2,Cell line enhanced,,A-431: 9.4;PC-3: 5.0;RPTEC TERT1: 4.7;RT4: 13.5;U-2 OS: 6.9
201,TDRD12,"ECAT8, FLJ13072",ENSG00000173809,Tudor domain containing 12,19,32719753-32829580,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,8,epididymis: 10.9;testis: 33.5,ovary: 2.6,Group enriched,34.0,HDLM-2: 23.6;NTERA-2: 93.5
202,TTC25,DKFZP434H0115,ENSG00000204815,Tetratricopeptide repeat domain 25,17,41930635-41965651,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA023908,Enhanced,,,,,Mixed,Group enriched,8,fallopian tube: 47.3;testis: 70.5,parathyroid gland: 7.4,Cell line enhanced,,SCLC-21H: 4.9;U-87 MG: 4.8
203,TTLL10,"FLJ36119, TTLL5",ENSG00000162571,Tubulin tyrosine ligase like 10,1,1173884-1197935,Predicted intracellular proteins,Evidence at protein level,HPA042712,Uncertain,,,,Endometrial cancer:1.61e-5 (favourable),Mixed,Group enriched,8,fallopian tube: 14.2;testis: 27.9,lung: 2.7,Cell line enriched,31.0,SCLC-21H: 27.2
204,WDR62,"C19orf14, DKFZP434J046, FLJ33298, MCPH2",ENSG00000075702,WD repeat domain 62,19,36054881-36105106,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA043255, HPA043639, CAB046468",Enhanced,,Enhanced,Microtubule organizing center<br>Cytosol,,Mixed,Group enriched,8,skeletal muscle: 15.9;testis: 76.4,heart muscle: 6.0,Mixed,,
205,ZNF474,"4933409D10Rik, FLJ32921",ENSG00000164185,Zinc finger protein 474,5,122129513-122153571,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Group enriched,8,fallopian tube: 26.7;testis: 13.4,lung: 2.5,Mixed,,
206,AGBL2,"CCP2, FLJ23598",ENSG00000165923,ATP/GTP binding protein like 2,11,47659591-47715389,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007718,Uncertain,,,,,Mixed,Group enriched,7,fallopian tube: 15.3;testis: 22.6,epididymis: 2.8,Cell line enhanced,,CAPAN-2: 4.0
207,BTBD16,"C10orf87, Em:AC061711.1, FLJ25359",ENSG00000138152,BTB domain containing 16,10,122271306-122338162,Predicted intracellular proteins,Evidence at protein level,"HPA040529, HPA057638",Uncertain,,Uncertain,Nucleoli<br>Cytosol,Renal cancer:1.50e-4 (unfavourable),Tissue enriched,Group enriched,7,skin: 9.9;testis: 14.2;urinary bladder: 19.0,liver: 2.1,Cell line enriched,9.0,RT4: 26.9
208,C9orf129,bA165J3.3,ENSG00000204352,Chromosome 9 open reading frame 129,9,93318199-93346414,Predicted intracellular proteins,Evidence at transcript level,HPA071515,,,Uncertain,Mitochondria,,Not detected,Group enriched,7,cerebral cortex: 4.1;testis: 1.7,epididymis: 0.4,Cell line enriched,9.0,NTERA-2: 2.1
209,CCDC103,"CILD17, FLJ13094, FLJ34211, PR46b",ENSG00000167131,Coiled-coil domain containing 103,17,44899142-44905390,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA043131,,,Approved,Cytosol,,Not detected,Group enriched,7,fallopian tube: 24.5;testis: 27.0,thyroid gland: 3.6,Cell line enhanced,,A549: 10.3;U-87 MG: 9.5
210,CFAP43,"bA373N18.2, C10orf79, FLJ22944, FLJ36006, WDR96",ENSG00000197748,Cilia and flagella associated protein 43,10,104129888-104232362,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Group enriched,7,fallopian tube: 78.0;testis: 103.2,lung: 12.5,Cell line enhanced,,CAPAN-2: 3.7;U-266/70: 2.5
211,CFAP45,"CCDC19, NESG1",ENSG00000213085,Cilia and flagella associated protein 45,1,159872364-159900163,Predicted intracellular proteins,Evidence at protein level,"HPA042204, HPA043618",Enhanced,,Enhanced,Nucleoplasm,,Tissue enhanced,Group enriched,7,fallopian tube: 71.3;testis: 38.9,lung: 7.7,Cell line enhanced,,BEWO: 8.7;HEL: 11.0
212,CFAP65,"CCDC108, DKFZp434O0527, MGC35338",ENSG00000181378,Cilia and flagella associated protein 65,2,219002846-219041527,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA055156,Uncertain,,,,Endometrial cancer:6.08e-5 (favourable),Tissue enhanced,Group enriched,7,fallopian tube: 41.2;testis: 17.7,lung: 3.9,Cell line enhanced,,SH-SY5Y: 1.0
213,CLEC18A,MRCL,ENSG00000157322,C-type lectin domain family 18 member A,16,69950705-69964452,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048976,Uncertain,,,,,Tissue enriched,Group enriched,7,kidney: 15.7;testis: 3.7,adrenal gland: 1.3,Not detected,,
214,CSMD3,,ENSG00000164796,CUB and Sushi multiple domains 3,8,112222928-113437099,Predicted membrane proteins,Evidence at transcript level,HPA029007,Uncertain,,,,,Not detected,Group enriched,7,cerebral cortex: 4.9;testis: 1.8,"fallopian tube,prostate,spleen: 0.4",Not detected,,
215,DNAJB13,"RSPH16A, TSARG6",ENSG00000187726,DnaJ heat shock protein family (Hsp40) member B13,11,73950319-73970366,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA052465, HPA061330",Enhanced,,Approved,Plasma membrane,Renal cancer:2.10e-6 (unfavourable),Tissue enhanced,Group enriched,7,fallopian tube: 76.0;testis: 19.1,"cervix, uterine,epididymis: 6.4",Cell line enhanced,,RPTEC TERT1: 3.3
216,ESRRB,"DFNB35, ERR2, ERRb, ERRbeta, ESRL2, NR3B2",ENSG00000119715,Estrogen related receptor beta,14,76310614-76501841,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Mixed,Group enriched,7,heart muscle: 2.3;kidney: 5.2;skeletal muscle: 1.7;stomach: 1.5;testis: 1.4,breast: 0.3,Cell line enhanced,,HMC-1: 1.0;K-562: 3.3;U-266/70: 1.2
217,FAM216A,"C12orf24, HSU79274",ENSG00000204856,Family with sequence similarity 216 member A,12,110468364-110490385,Predicted intracellular proteins,Evidence at protein level,HPA038286,Enhanced,,Approved,Actin filaments,"Renal cancer:4.18e-10 (unfavourable), Liver cancer:4.49e-5 (unfavourable)",Expressed in all,Group enriched,7,cerebral cortex: 16.2;testis: 61.1,appendix: 5.5,Mixed,,
218,FSIP1,FLJ35989,ENSG00000150667,Fibrous sheath interacting protein 1,15,39600031-39782830,Predicted intracellular proteins,Evidence at protein level,HPA041002,Uncertain,,Uncertain,Nucleoplasm,,Tissue enriched,Group enriched,7,colon: 11.2;rectum: 18.4;testis: 13.6,breast: 2.2,Mixed,,
219,GALNT8,GALNAC-T8,ENSG00000130035,Polypeptide N-acetylgalactosaminyltransferase 8,12,4720341-4851927,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012638, HPA014418, HPA073461",Approved,,Approved,Vesicles,,Tissue enhanced,Group enriched,7,cerebral cortex: 19.4;colon: 17.6;duodenum: 8.1;rectum: 40.6;small intestine: 18.9;testis: 26.5,appendix: 3.2,Cell line enhanced,,Karpas-707: 24.5;NTERA-2: 12.1;U-2 OS: 4.6;U-266/84: 7.3
220,HEATR4,MGC48595,ENSG00000187105,HEAT repeat containing 4,14,73478484-73558947,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,7,skin: 4.4;testis: 21.6,"duodenum,lymph node: 1.9",Cell line enhanced,,SCLC-21H: 2.9
221,IGLON5,LOC402665,ENSG00000142549,IgLON family member 5,19,51311848-51330354,Predicted secreted proteins,Evidence at protein level,HPA041994,Approved,,Uncertain,Nucleus,Renal cancer:5.62e-7 (unfavourable),Tissue enhanced,Group enriched,7,adrenal gland: 2.3;cerebral cortex: 11.1;testis: 9.5,"esophagus,seminal vesicle: 1.0",Group enriched,8.0,HMC-1: 30.8;NTERA-2: 16.0;SH-SY5Y: 24.3;U-2 OS: 6.9
222,KCTD16,KIAA1317,ENSG00000183775,Potassium channel tetramerization domain containing 16,5,144170832-144485686,Predicted intracellular proteins,Evidence at protein level,"HPA044590, HPA050154",Approved,,Approved,Nuclear speckles,,Tissue enhanced,Group enriched,7,cerebral cortex: 12.3;testis: 3.0,lung: 1.1,Cell line enhanced,,SCLC-21H: 5.4;TIME: 7.3
223,KHDRBS3,"Etle, etoile, SALP, SLM-2, SLM2, T-STAR",ENSG00000131773,"KH RNA binding domain containing, signal transduction associated 3",8,135457457-135656722,Predicted intracellular proteins,Evidence at protein level,"HPA000275, HPA000500, HPA000981",Enhanced,,Supported,Nucleoplasm,Renal cancer:7.16e-6 (favourable),Expressed in all,Group enriched,7,cerebral cortex: 89.1;testis: 285.9,epididymis: 27.8,Cell line enhanced,,WM-115: 83.8
224,KRTAP21-1,KAP21.1,ENSG00000187005,Keratin associated protein 21-1,21,30754830-30755428,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,7,breast: 13.5;testis: 6.0,seminal vesicle: 1.3,Cell line enhanced,,SK-MEL-30: 1.2
225,LMNTD1,"FLJ36004, IFLTD1, Pas1c1",ENSG00000152936,Lamin tail domain containing 1,12,25409307-25648579,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,"HPA038640, HPA045911",Uncertain,,Approved,Nucleoplasm<br>Centrosome,,Tissue enhanced,Group enriched,7,fallopian tube: 27.1;testis: 26.6,rectum: 3.7,Cell line enhanced,,SH-SY5Y: 8.1;U-2197: 24.9
226,LRP8,"APOER2, HSZ75190, LRP-8, MCI1",ENSG00000157193,LDL receptor related protein 8,1,53242364-53328070,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA073031,Enhanced,,,,"Endometrial cancer:3.46e-6 (unfavourable), Lung cancer:7.02e-4 (unfavourable)",Mixed,Group enriched,7,cerebral cortex: 25.2;testis: 46.9;thyroid gland: 87.5,appendix: 7.7,Expressed in all,,
227,LRRC23,"B7, LRPB7",ENSG00000010626,Leucine rich repeat containing 23,12,6873569-6914243,Predicted intracellular proteins,Evidence at protein level,"HPA037766, HPA057533",Enhanced,,Supported,Nucleoli,Breast cancer:6.02e-4 (favourable),Expressed in all,Group enriched,7,fallopian tube: 165.3;testis: 43.3,epididymis: 15.2,Mixed,,
228,LRRC3B,LRP15,ENSG00000179796,Leucine rich repeat containing 3B,3,26622806-26710776,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA015568,Approved,,,,,Group enriched,Group enriched,7,cerebral cortex: 19.2;skeletal muscle: 3.9;testis: 13.0,"endometrium,ovary: 1.6",Cell line enhanced,,NTERA-2: 1.6
229,LRRIQ1,"FLJ12303, KIAA1801",ENSG00000133640,Leucine rich repeats and IQ motif containing 1,12,85036314-85263224,Predicted intracellular proteins,Evidence at protein level,HPA046162,Uncertain,,,,,Mixed,Group enriched,7,fallopian tube: 13.7;testis: 25.7,parathyroid gland: 2.9,Cell line enhanced,,RPTEC TERT1: 2.2;SH-SY5Y: 2.1
230,MROH9,"ARMC11, C1orf129, FLJ23550",ENSG00000117501,Maestro heat like repeat family member 9,1,170935471-171064765,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,7,fallopian tube: 3.9;lung: 1.2;testis: 2.7,endometrium: 0.3,Not detected,,
231,MSANTD1,"C4orf44, LOC345222",ENSG00000188981,Myb/SANT DNA binding domain containing 1,4,3244369-3271738,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,7,cerebral cortex: 1.9;testis: 2.4,"epididymis,lung,spleen: 0.3",Not detected,,
232,MSH4,,ENSG00000057468,MutS homolog 4,1,75796882-75913238,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,7,epididymis: 2.3;testis: 7.7,spleen: 0.7,Cell line enhanced,,AN3-CA: 1.6
233,NAT8L,"FLJ37478, Hcml3",ENSG00000185818,N-acetyltransferase 8 like,4,2059512-2069089,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040677,,,Supported,Mitochondria,Endometrial cancer:1.01e-5 (unfavourable),Group enriched,Group enriched,7,adipose tissue: 48.6;cerebral cortex: 64.9;testis: 19.0,kidney: 6.7,Cell line enhanced,,SCLC-21H: 32.4
234,NOL4,"CT125, HRIHFB2255, NOLP",ENSG00000101746,Nucleolar protein 4,18,33851100-34224952,Predicted intracellular proteins,Evidence at protein level,HPA046740,,,Supported,Nucleus,,Tissue enhanced,Group enriched,7,cerebral cortex: 15.9;testis: 22.8,thyroid gland: 2.9,Cell line enhanced,,SCLC-21H: 44.1;SH-SY5Y: 10.6;U-698: 5.7
235,OPRK1,"KOR, OPRK",ENSG00000082556,Opioid receptor kappa 1,8,53225716-53251697,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"CAB022595, HPA067549",Uncertain,,Supported,Nucleus<br>Plasma membrane<br>Cytosol,,Tissue enhanced,Group enriched,7,cerebral cortex: 3.6;prostate: 2.8;testis: 1.3,"placenta,skeletal muscle: 0.3",Group enriched,7.0,AF22: 4.5;U-937: 17.3
236,PIH1D2,,ENSG00000150773,PIH1 domain containing 2,11,112064010-112074274,Predicted intracellular proteins,Evidence at protein level,HPA039496,,,Uncertain,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,7,fallopian tube: 35.4;testis: 126.7,thyroid gland: 11.6,Mixed,,
237,POPDC3,"bA355M14.1, MGC22671, POP3",ENSG00000132429,Popeye domain containing 3,6,105158280-105179995,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012514,,,Approved,Nucleoli<br>Cytosol,"Head and neck cancer:4.43e-4 (unfavourable), Lung cancer:5.79e-4 (unfavourable)",Mixed,Group enriched,7,cerebral cortex: 8.8;heart muscle: 19.8;skeletal muscle: 41.8;testis: 9.1,epididymis: 2.9,Cell line enhanced,,RH-30: 20.5
238,PRDM9,"KMT8B, MSBP3, PFM6, ZNF899",ENSG00000164256,PR/SET domain 9,5,23443586-23528597,"Enzymes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059555,Uncertain,,,,,Not detected,Group enriched,7,epididymis: 1.7;testis: 7.1,bone marrow: 0.6,Cell line enriched,7.0,U-266/70: 5.0
239,REEP6,"C19orf32, DP1L1, FLJ25383, Yip2f",ENSG00000115255,Receptor accessory protein 6,19,1490747-1497927,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA003895, HPA048015",Enhanced,,Supported,Endoplasmic reticulum,,Expressed in all,Group enriched,7,adrenal gland: 48.2;duodenum: 166.1;liver: 76.1;small intestine: 167.0;testis: 181.2,prostate: 19.3,Cell line enhanced,,K-562: 101.6;T-47d: 84.9
240,RIBC1,FLJ32783,ENSG00000158423,RIB43A domain with coiled-coils 1,X,53422690-53431120,Predicted intracellular proteins,Evidence at protein level,"HPA001150, HPA021613",Uncertain,,Approved,Nuclear bodies,"Cervical cancer:1.90e-5 (favourable), Endometrial cancer:9.66e-4 (favourable)",Mixed,Group enriched,7,fallopian tube: 45.0;testis: 41.7,thyroid gland: 6.1,Cell line enhanced,,T-47d: 7.4
241,RSPH10B2,,ENSG00000169402,Radial spoke head 10 homolog B2,7,6754109-6799365,Predicted intracellular proteins,Evidence at protein level,HPA049182,Supported,,,,,Not detected,Group enriched,7,fallopian tube: 16.1;testis: 35.8,parathyroid gland: 3.6,Not detected,,
242,SALL4,"dJ1112F19.1, ZNF797",ENSG00000101115,Spalt like transcription factor 4,20,51782331-51802520,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA015291, HPA015791",Enhanced,,Enhanced,Nucleoplasm,,Tissue enriched,Group enriched,7,parathyroid gland: 6.7;prostate: 1.4;testis: 5.8;thyroid gland: 3.5,urinary bladder: 0.6,Cell line enhanced,,AF22: 24.7;AN3-CA: 16.2;BEWO: 32.0;NTERA-2: 60.1;SiHa: 16.5
243,SH2D5,,ENSG00000189410,SH2 domain containing 5,1,20719732-20732837,Predicted intracellular proteins,Evidence at protein level,HPA030182,,,Supported,Cytosol,,Tissue enhanced,Group enriched,7,cerebral cortex: 16.6;placenta: 5.1;testis: 9.9,thyroid gland: 1.5,Cell line enhanced,,HBEC3-KT: 34.9;hTERT-HME1: 46.6
244,SH2D7,LOC646892,ENSG00000183476,SH2 domain containing 7,15,78077808-78104909,Predicted intracellular proteins,Evidence at transcript level,HPA051320,Approved,,,,,Mixed,Group enriched,7,colon: 1.6;duodenum: 2.1;small intestine: 1.9;testis: 5.7,cerebral cortex: 0.4,Cell line enhanced,,SH-SY5Y: 1.4
245,SHC4,"RaLP, SHCD",ENSG00000185634,SHC adaptor protein 4,15,48823735-48963444,"Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA074146,,,Approved,Cytosol,,Tissue enhanced,Group enriched,7,cerebral cortex: 13.1;testis: 20.1,gallbladder: 2.3,Cell line enhanced,,AN3-CA: 9.5;SK-MEL-30: 15.2;WM-115: 16.3
246,SPA17,"CT22, SP17",ENSG00000064199,Sperm autoantigenic protein 17,11,124673798-124697518,Predicted intracellular proteins,Evidence at protein level,HPA037568,Enhanced,,Approved,Vesicles,Endometrial cancer:1.03e-4 (favourable),Expressed in all,Group enriched,7,fallopian tube: 124.1;testis: 430.2,epididymis: 38.3,Mixed,,
247,TCEAL5,WEX4,ENSG00000204065,Transcription elongation factor A like 5,X,103273691-103276872,Predicted intracellular proteins,Evidence at protein level,"HPA045564, HPA058982, HPA072199",Supported,,Uncertain,Nucleoplasm<br>Cytosol,"Pancreatic cancer:8.60e-4 (favourable), Endometrial cancer:9.09e-4 (unfavourable)",Tissue enhanced,Group enriched,7,cerebral cortex: 82.5;testis: 82.5,adrenal gland: 11.9,Group enriched,7.0,SCLC-21H: 9.3;SH-SY5Y: 25.9
248,TEKT1,,ENSG00000167858,Tektin 1,17,6789133-6831761,Predicted intracellular proteins,Evidence at protein level,"HPA044444, HPA062285",Approved,,,,Endometrial cancer:6.08e-4 (favourable),Group enriched,Group enriched,7,fallopian tube: 79.5;testis: 16.7,lung: 6.9,Not detected,,
249,TEX30,C13orf27,ENSG00000151287,Testis expressed 30,13,102765990-102773811,Predicted intracellular proteins,Evidence at protein level,HPA053545,Enhanced,,,,"Prostate cancer:2.10e-6 (unfavourable), Cervical cancer:2.09e-5 (favourable)",Expressed in all,Group enriched,7,epididymis: 87.8;testis: 223.6,placenta: 22.3,Cell line enhanced,,NB-4: 184.1
250,UMODL1,,ENSG00000177398,Uromodulin like 1,21,42062959-42143453,Predicted membrane proteins,Evidence at protein level,HPA067245,Uncertain,,,,,Group enriched,Group enriched,7,fallopian tube: 1.7;testis: 1.7,small intestine: 0.2,Group enriched,6.0,SCLC-21H: 1.8;U-266/70: 2.9
251,ZIM2,ZNF656,ENSG00000269699,Zinc finger imprinted 2,19,56774552-56840729,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071856,,,Approved,Nuclear speckles<br>Cytosol,,Not detected,Group enriched,7,adrenal gland: 5.8;cerebral cortex: 5.1;ovary: 9.9;placenta: 6.8;testis: 7.7,endometrium: 1.0,Cell line enhanced,,BEWO: 4.7;Hep G2: 4.0;NTERA-2: 1.6;RH-30: 1.6;U-2 OS: 1.2
252,ABCG4,WHITE2,ENSG00000172350,ATP binding cassette subfamily G member 4,11,119149012-119162653,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA040312,Uncertain,,,,,Not detected,Group enriched,6,cerebral cortex: 6.6;parathyroid gland: 4.1;testis: 5.1,seminal vesicle: 0.8,Cell line enhanced,,AN3-CA: 1.7;HAP1: 1.0
253,AC005281.1,,ENSG00000226690,,7,12483344-12541910,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Group enriched,6,fallopian tube: 8.1;testis: 1.6,lung: 0.7,Cell line enhanced,,HAP1: 1.4
254,AC136616.1,,ENSG00000273554,,Unmapped,1139577-1147868,Predicted membrane proteins,Evidence at transcript level,,,,,,,,Group enriched,6,skin: 1.6;testis: 6.9,adrenal gland: 0.6,Cell line enriched,6.0,AN3-CA: 14.2
255,ACOXL,FLJ11042,ENSG00000153093,Acyl-CoA oxidase-like,2,110732573-111118222,Predicted intracellular proteins,Evidence at protein level,"HPA035392, HPA035393",,,Supported,Nucleoli<br>Cytosol,Urothelial cancer:6.48e-4 (favourable),Group enriched,Group enriched,6,epididymis: 9.2;lung: 14.5;parathyroid gland: 6.9;prostate: 5.2;testis: 5.2;urinary bladder: 7.6,thyroid gland: 1.3,Cell line enhanced,,A-431: 11.1;RPMI-8226: 15.9;RT4: 23.3;U-266/70: 14.6
256,ACSL6,"ACS2, FACL6, KIAA0837, LACS2, LACS5",ENSG00000164398,Acyl-CoA synthetase long-chain family member 6,5,131949973-132012243,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA040470,Enhanced,,,,,Group enriched,Group enriched,6,bone marrow: 18.0;cerebral cortex: 61.9;parathyroid gland: 22.5;seminal vesicle: 29.0;testis: 51.4,adrenal gland: 6.4,Group enriched,6.0,SCLC-21H: 13.0;U-937: 5.2
257,ANKMY1,"FLJ20499, ZMYND13",ENSG00000144504,Ankyrin repeat and MYND domain containing 1,2,240479422-240569209,Predicted intracellular proteins,Evidence at protein level,HPA026620,Uncertain,,Approved,Nucleus<br>Nuclear bodies<br>Cytosol,Urothelial cancer:3.20e-4 (favourable),Expressed in all,Group enriched,6,fallopian tube: 39.5;testis: 94.2,parathyroid gland: 11.4,Mixed,,
258,ANKRD55,FLJ11795,ENSG00000164512,Ankyrin repeat domain 55,5,56099678-56233359,Predicted intracellular proteins,Evidence at protein level,HPA051049,Approved,,,,,Tissue enriched,Group enriched,6,lymph node: 4.1;testis: 17.3,tonsil: 1.8,Group enriched,6.0,HEL: 30.8;HMC-1: 15.0;NB-4: 14.3
259,ATP6V1E2,"ATP6E1, ATP6EL2, ATP6V1EL2, MGC9341, VMA4",ENSG00000250565,ATPase H+ transporting V1 subunit E2,2,46490750-46542557,Predicted intracellular proteins,Evidence at protein level,HPA052784,Uncertain,,,,,Expressed in all,Group enriched,6,epididymis: 7.7;testis: 31.6,cerebral cortex: 3.2,Mixed,,
260,ATP8A2,"ATPIB, ML-1",ENSG00000132932,ATPase phospholipid transporting 8A2,13,25372071-26025851,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA039926, HPA040033",Approved,,Supported,Nucleoplasm<br>Plasma membrane,,Mixed,Group enriched,6,cerebral cortex: 26.4;testis: 10.7,adrenal gland: 2.9,Cell line enhanced,,HMC-1: 19.3;SCLC-21H: 3.9
261,C12orf60,MGC47869,ENSG00000182993,Chromosome 12 open reading frame 60,12,14803572-14906586,Predicted intracellular proteins,Evidence at protein level,HPA043911,,,Approved,Nucleus<br>Cytosol,,Mixed,Group enriched,6,adrenal gland: 5.9;testis: 23.9,kidney: 2.5,Mixed,,
262,C2orf70,LOC339778,ENSG00000173557,Chromosome 2 open reading frame 70,2,26562582-26579532,Predicted intracellular proteins,Evidence at protein level,HPA062453,Enhanced,,Approved,Nuclear membrane<br>Vesicles,Pancreatic cancer:6.49e-4 (favourable),Mixed,Group enriched,6,fallopian tube: 12.0;stomach: 4.9;testis: 17.5,thyroid gland: 1.9,Cell line enhanced,,A-431: 3.6;CAPAN-2: 2.7;EFO-21: 1.8;RPTEC TERT1: 2.8
263,C6orf118,"bA85G2.1, MGC23884",ENSG00000112539,Chromosome 6 open reading frame 118,6,165279664-165309607,Predicted intracellular proteins,Evidence at transcript level,"HPA029787, HPA029789",Approved,,Uncertain,Mitochondria,,Tissue enhanced,Group enriched,6,fallopian tube: 26.2;testis: 12.8,lung: 3.2,Cell line enhanced,,AF22: 2.7;SCLC-21H: 1.8
264,C9orf116,"MGC29761, PIERCE1, RbEST47",ENSG00000160345,Chromosome 9 open reading frame 116,9,135495181-135501734,Predicted intracellular proteins,Evidence at protein level,"HPA021439, HPA065287",Approved,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:3.53e-5 (favourable),Expressed in all,Group enriched,6,epididymis: 31.1;fallopian tube: 154.4;testis: 63.3,thyroid gland: 13.6,Cell line enhanced,,T-47d: 39.2;U-2197: 39.8
265,CCDC180,"BDAG1, C9orf174, DKFZp434I2420, KIAA1529",ENSG00000197816,Coiled-coil domain containing 180,9,97307304-97378524,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,6,fallopian tube: 15.8;testis: 37.9,lung: 4.8,Cell line enhanced,,HDLM-2: 3.9;U-266/70: 4.4
266,CDC20B,FLJ37927,ENSG00000164287,Cell division cycle 20B,5,55112995-55173175,Predicted intracellular proteins,Evidence at protein level,HPA053900,Uncertain,,,,,Tissue enhanced,Group enriched,6,endometrium: 1.2;fallopian tube: 3.4;kidney: 1.2;testis: 4.9,lung: 0.4,Not detected,,
267,CELSR3,"ADGRC3, CDHF11, EGFL1, FMI1, HFMI1, MEGF2",ENSG00000008300,Cadherin EGF LAG seven-pass G-type receptor 3,3,48636469-48662915,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA062866,Approved,,,,,Mixed,Group enriched,6,adrenal gland: 1.6;cerebral cortex: 5.9;testis: 3.5,"parathyroid gland,stomach: 0.6",Cell line enhanced,,SH-SY5Y: 19.4;SiHa: 17.5
268,CFAP61,"C20orf26, CaM-IP3, dJ1002M8.3, DKFZP434K156",ENSG00000089101,Cilia and flagella associated protein 61,20,20052514-20360702,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA009079,Uncertain,,,,,Mixed,Group enriched,6,fallopian tube: 20.3;heart muscle: 8.5;testis: 29.5,skeletal muscle: 3.3,Cell line enhanced,,HMC-1: 2.1;SCLC-21H: 6.6;U-87 MG: 4.1
269,COL9A3,"DJ885L7.4.1, EDM3, FLJ90759, IDD, MED",ENSG00000092758,Collagen type IX alpha 3 chain,20,62816244-62841159,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA040125, HPA058323",Supported,,Approved,Nucleoplasm<br>Intermediate filaments,,Mixed,Group enriched,6,cerebral cortex: 7.5;salivary gland: 10.5;testis: 6.3;thyroid gland: 19.1,seminal vesicle: 1.8,Group enriched,6.0,BEWO: 139.2;Hep G2: 40.1;SK-MEL-30: 37.9;WM-115: 57.3
270,DNAH10,FLJ43808,ENSG00000197653,Dynein axonemal heavy chain 10,12,123762188-123936206,Predicted intracellular proteins,Evidence at protein level,HPA039066,Enhanced,,,,,Tissue enhanced,Group enriched,6,fallopian tube: 5.6;testis: 5.6,lung: 0.9,Not detected,,
271,DOCK3,"KIAA0299, MOCA, PBP",ENSG00000088538,Dedicator of cytokinesis 3,3,50675241-51384198,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA037543, HPA037544",Approved,,Enhanced,Cytosol,,Tissue enhanced,Group enriched,6,cerebral cortex: 33.7;parathyroid gland: 12.6;testis: 8.5;thyroid gland: 15.1,adrenal gland: 3.0,Cell line enhanced,,AN3-CA: 5.9;U-87 MG: 8.0
272,DUSP13,"BEDP, DUSP13A, DUSP13B, FLJ32450, TMDP",ENSG00000079393,Dual specificity phosphatase 13,10,75094432-75109221,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,6,skeletal muscle: 84.9;testis: 47.5,heart muscle: 10.9,Cell line enhanced,,BEWO: 4.2;EFO-21: 4.7;Hep G2: 7.4;K-562: 3.8;LHCN-M2: 7.9;RH-30: 7.7
273,EFHB,"CFAP21, FLJ25200",ENSG00000163576,EF-hand domain family member B,3,19879472-19947025,Predicted intracellular proteins,Evidence at protein level,HPA078067,,,Approved,Nucleoli,,Mixed,Group enriched,6,fallopian tube: 25.5;testis: 25.8,cerebral cortex: 4.3,Cell line enriched,30.0,RPTEC TERT1: 14.9
274,ERICH3,"C1orf173, DKFZp547I048, RP11-653A5.1",ENSG00000178965,Glutamate rich 3,1,74568111-74673738,Predicted intracellular proteins,Evidence at protein level,HPA028655,Approved,,,,Endometrial cancer:1.56e-5 (favourable),Tissue enhanced,Group enriched,6,"cerebral cortex: 18.9;cervix, uterine: 8.6;fallopian tube: 27.7;testis: 43.1",lung: 4.2,Not detected,,
275,FAM133A,"CT115, FLJ37659, RP1-32F7.2",ENSG00000179083,Family with sequence similarity 133 member A,X,93674013-93712274,Predicted intracellular proteins,Evidence at protein level,"HPA066175, HPA069513",,,Approved,Nucleus<br>Nucleoli,,Mixed,Group enriched,6,cerebral cortex: 5.3;testis: 14.1,adrenal gland: 1.5,Cell line enhanced,,Karpas-707: 33.0;U-2197: 22.2;U-266/70: 27.2;U-266/84: 58.1
276,FAM221B,C9orf128,ENSG00000204930,Family with sequence similarity 221 member B,9,35816391-35828747,Predicted intracellular proteins,Evidence at transcript level,"HPA023011, HPA026577",Uncertain,,,,,Not detected,Group enriched,6,bone marrow: 2.4;testis: 10.3,prostate: 1.1,Not detected,,
277,FHAD1,KIAA1937,ENSG00000142621,Forkhead associated phosphopeptide binding domain 1,1,15247272-15400283,Predicted intracellular proteins,Evidence at protein level,HPA054284,Enhanced,,,,,Mixed,Group enriched,6,fallopian tube: 24.1;lung: 5.2;testis: 24.7,"cervix, uterine: 3.1",Group enriched,5.0,HDLM-2: 27.2;HMC-1: 70.7;K-562: 16.4;U-87 MG: 42.0
278,GPR137C,"DKFZp762F0713, TM7SF1L2",ENSG00000180998,G protein-coupled receptor 137C,14,52553148-52637713,Predicted membrane proteins,Evidence at transcript level,"HPA003640, HPA030763",Uncertain,,Approved,Vesicles,,Mixed,Group enriched,6,cerebral cortex: 18.0;epididymis: 10.8;testis: 6.8,gallbladder: 2.1,Mixed,,
279,HAVCR1,"CD365, HAVCR, HAVCR-1, KIM1, TIM-1, TIM1, TIMD1",ENSG00000113249,Hepatitis A virus cellular receptor 1,5,157029413-157059119,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007173, CAB075697",Approved,,Approved,Vesicles,"Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable)",Tissue enriched,Group enriched,6,colon: 4.8;kidney: 8.3;rectum: 4.1;testis: 1.7,gallbladder: 0.8,Group enriched,5.0,A549: 86.4;CACO-2: 95.7;RPTEC TERT1: 33.8
280,HCN4,,ENSG00000138622,Hyperpolarization activated cyclic nucleotide gated potassium channel 4,15,73319859-73369264,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Group enriched,Group enriched,6,cerebral cortex: 1.4;heart muscle: 1.5;testis: 6.7,adrenal gland: 0.5,Cell line enhanced,,AF22: 1.2;CACO-2: 1.3;NTERA-2: 4.7;U-2 OS: 2.1
281,HRASLS,"H-REV107, HRASLS1",ENSG00000127252,HRAS like suppressor,3,193241125-193277738,Predicted membrane proteins,Evidence at transcript level,HPA051179,Uncertain,,Approved,Focal adhesion sites<br>Cytosol,Testis cancer:4.36e-4 (favourable),Mixed,Group enriched,6,skeletal muscle: 27.2;testis: 95.8,thyroid gland: 10.0,Cell line enhanced,,HAP1: 11.5;PC-3: 20.0;SCLC-21H: 22.9;U-2 OS: 12.2;U-251 MG: 12.7
282,IGF2BP1,IMP-1,ENSG00000159217,Insulin like growth factor 2 mRNA binding protein 1,17,48997412-49055650,Predicted intracellular proteins,Evidence at protein level,"HPA021367, HPA062273",Enhanced,,Supported,Cytosol,,Tissue enriched,Group enriched,6,placenta: 8.0;testis: 9.1,kidney: 1.4,Cell line enhanced,,AF22: 145.0;CACO-2: 196.9;REH: 127.4
283,IQCD,"CFAP84, DRC10",ENSG00000166578,IQ motif containing D,12,113195441-113221094,Predicted intracellular proteins,Evidence at protein level,"HPA046810, HPA048782",Supported,,Approved,Nucleus,Pancreatic cancer:3.90e-4 (favourable),Mixed,Group enriched,6,fallopian tube: 34.8;testis: 65.4,parathyroid gland: 7.7,Cell line enhanced,,BJ hTERT+: 22.7
284,IQCG,"CFAP122, DKFZp434B227, DRC9",ENSG00000114473,IQ motif containing G,3,197889075-197960142,Predicted intracellular proteins,Evidence at protein level,"HPA042787, HPA051981",Enhanced,,Approved,Actin filaments<br>Cytosol,,Expressed in all,Group enriched,6,fallopian tube: 83.6;testis: 78.8,thyroid gland: 13.9,Expressed in all,,
285,KIF6,"C6orf102, dJ1043E3.1, dJ137F1.4, dJ188D3.1, DKFZp451I2418, MGC33317",ENSG00000164627,Kinesin family member 6,6,39329990-39725405,Predicted intracellular proteins,Evidence at protein level,"HPA038811, HPA058624",Enhanced,,Approved,Centrosome,,Mixed,Group enriched,6,cerebral cortex: 7.0;fallopian tube: 6.0;testis: 9.6,lung: 1.2,Cell line enhanced,,RPMI-8226: 6.3;SCLC-21H: 14.3;SK-MEL-30: 4.0
286,LRRC63,RP11-139H14.4,ENSG00000173988,Leucine rich repeat containing 63,13,46211943-46277366,Predicted intracellular proteins,Evidence at transcript level,"HPA039318, HPA039763",Uncertain,,Approved,Golgi apparatus,,Not detected,Group enriched,6,cerebral cortex: 1.1;epididymis: 1.7;testis: 2.4,fallopian tube: 0.3,Cell line enhanced,,HDLM-2: 1.1
287,MNS1,"FLJ11222, SPATA40",ENSG00000138587,Meiosis specific nuclear structural 1,15,56421544-56465137,Predicted intracellular proteins,Evidence at protein level,"HPA039975, HPA040382",Uncertain,,Approved,Nucleoplasm<br>Nuclear speckles,,Expressed in all,Group enriched,6,fallopian tube: 33.7;testis: 86.9,kidney: 9.7,Mixed,,
288,MORN5,"C9orf113, C9orf18, FLJ46909",ENSG00000185681,MORN repeat containing 5,9,122159908-122200088,Predicted intracellular proteins,Evidence at transcript level,,,,,,Endometrial cancer:4.86e-4 (favourable),Tissue enhanced,Group enriched,6,fallopian tube: 175.5;testis: 106.4,smooth muscle: 24.7,Cell line enhanced,,NB-4: 1.0;U-87 MG: 1.1
289,NXF2B,bA353J17.1,ENSG00000269437,Nuclear RNA export factor 2B,X,102360395-102463274,Predicted intracellular proteins,Evidence at protein level,HPA002079,Uncertain,,,,,Not detected,Group enriched,6,epididymis: 19.1;testis: 4.9,fallopian tube: 2.1,Cell line enriched,30.0,U-266/84: 25.0
290,ONECUT1,"HNF-6, HNF6, HNF6A",ENSG00000169856,One cut homeobox 1,15,52756989-52791078,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003457,Enhanced,,,,,Group enriched,Group enriched,6,gallbladder: 8.4;liver: 5.9;pancreas: 2.3;testis: 1.8,bone marrow: 0.7,Cell line enhanced,,MCF7: 1.7;WM-115: 1.5
291,PGPEP1L,,ENSG00000183571,Pyroglutamyl-peptidase I-like,15,98968230-99007795,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA041781,Uncertain,,,,,Not detected,Group enriched,6,heart muscle: 2.4;skeletal muscle: 10.5;testis: 3.8,"breast,esophagus: 0.9",Cell line enhanced,,U-2 OS: 1.1
292,PPM1J,"DKFZp434P1514, FLJ35951, MGC19531, PP2Czeta, PPP2CZ",ENSG00000155367,"Protein phosphatase, Mg2+/Mn2+ dependent 1J",1,112709994-112715477,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046045,Uncertain,,Approved,Vesicles,,Mixed,Group enriched,6,epididymis: 22.8;skeletal muscle: 24.1;skin: 21.4;testis: 46.5,heart muscle: 4.7,Cell line enhanced,,T-47d: 18.2
293,PPP1R36,C14orf50,ENSG00000165807,Protein phosphatase 1 regulatory subunit 36,14,64549902-64589380,Predicted intracellular proteins,Evidence at protein level,HPA077492,Enhanced,,,,,Mixed,Group enriched,6,fallopian tube: 17.4;testis: 58.9,duodenum: 6.6,Group enriched,6.0,CAPAN-2: 12.6;SCLC-21H: 3.4
294,PRSS42,TESSP2,ENSG00000178055,"Protease, serine 42",3,46829542-46834095,"Enzymes, Predicted secreted proteins",Evidence at transcript level,HPA046925,Uncertain,,,,,Not detected,Group enriched,6,epididymis: 4.8;heart muscle: 8.8;parathyroid gland: 3.1;skeletal muscle: 8.4;testis: 2.0;thyroid gland: 1.9,"breast,cervix, uterine,prostate,seminal vesicle: 0.7",Cell line enhanced,,NTERA-2: 1.0
295,RLN3,"H3, RXN3, ZINS4",ENSG00000171136,Relaxin 3,19,14028148-14031042,Predicted secreted proteins,Evidence at protein level,HPA043731,Uncertain,,,,,Not detected,Group enriched,6,parathyroid gland: 2.9;testis: 3.3,spleen: 0.5,Not detected,,
296,RSPH9,"C6orf206, CILD12, FLJ30845, MRPS18AL1",ENSG00000172426,Radial spoke head 9 homolog,6,43645046-43672599,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA031703,Enhanced,,,,,Mixed,Group enriched,6,fallopian tube: 13.4;testis: 12.2,lung: 2.0,Cell line enhanced,,U-87 MG: 2.1
297,RTBDN,FLJ36353,ENSG00000132026,Retbindin,19,12825478-12835428,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA052511,,,Approved,Endoplasmic reticulum,,Mixed,Group enriched,6,adrenal gland: 4.6;cerebral cortex: 14.6;testis: 3.5,stomach: 1.2,Cell line enhanced,,SCLC-21H: 9.8;SH-SY5Y: 5.8;U-266/84: 16.0
298,SFMBT1,"DKFZp434L243, RU1, SFMBT",ENSG00000163935,Scm-like with four mbt domains 1,3,52903572-53046750,Predicted intracellular proteins,Evidence at protein level,"HPA036152, HPA064564",,,Enhanced,Nucleoplasm,Endometrial cancer:3.86e-4 (unfavourable),Expressed in all,Group enriched,6,parathyroid gland: 32.9;testis: 83.1,thyroid gland: 9.9,Expressed in all,,
299,SH3TC2,"CMT4C, KIAA1985",ENSG00000169247,SH3 domain and tetratricopeptide repeats 2,5,148923639-149063163,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA037683, HPA037684",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,6,cerebral cortex: 3.0;placenta: 2.8;testis: 8.8,"cervix, uterine,heart muscle: 0.7",Cell line enhanced,,RT4: 6.6;SK-MEL-30: 5.9;WM-115: 8.2
300,SLC4A5,NBC4,ENSG00000188687,Solute carrier family 4 member 5,2,74216242-74343414,"Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA036621,Approved,,,,,Tissue enriched,Group enriched,6,testis: 30.9;thyroid gland: 44.9,skin: 6.3,Cell line enhanced,,U-266/70: 7.2
301,SRSF12,"SFRS13B, SFRS19, SRrp35",ENSG00000154548,Serine and arginine rich splicing factor 12,6,89095959-89118081,Predicted intracellular proteins,Evidence at protein level,HPA049782,Approved,,,,,Mixed,Group enriched,6,cerebral cortex: 6.9;testis: 20.9,"parathyroid gland,thyroid gland: 2.1",Cell line enhanced,,AF22: 9.1;AN3-CA: 8.8;HAP1: 7.7;HEK93: 7.0;REH: 6.9;SCLC-21H: 9.5;SH-SY5Y: 8.4
302,TCEAL6,WEX2,ENSG00000204071,Transcription elongation factor A like 6,X,102140476-102142970,Predicted intracellular proteins,Evidence at protein level,"HPA045564, HPA058982",Supported,,,,,Tissue enriched,Group enriched,6,adrenal gland: 14.3;cerebral cortex: 63.5;testis: 34.6,endometrium: 5.8,Not detected,,
303,TDRD6,"bA446F17.4, CT41.2, NY-CO-45, SPATA36",ENSG00000180113,Tudor domain containing 6,6,46687875-46704319,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,6,testis: 42.8;thyroid gland: 10.1,"appendix,lymph node: 4.7",Not detected,,
304,TDRD9,"C14orf75, DKFZp434N0820, FLJ36164, NET54",ENSG00000156414,Tudor domain containing 9,14,103928462-104052667,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Thyroid cancer:5.52e-4 (unfavourable),Mixed,Group enriched,6,parathyroid gland: 39.7;testis: 75.0,thyroid gland: 9.1,Cell line enhanced,,HDLM-2: 22.6;HeLa: 13.9;HMC-1: 82.8;RPTEC TERT1: 19.5
305,TIMD4,,ENSG00000145850,T-cell immunoglobulin and mucin domain containing 4,5,156919282-156963255,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA015625, CAB026027",Approved,,,,Renal cancer:3.37e-4 (favourable),Tissue enriched,Group enriched,6,lymph node: 63.6;testis: 163.0,adipose tissue: 17.9,Group enriched,16.0,U-266/70: 73.7;U-266/84: 19.8
306,TMPRSS6,FLJ30744,ENSG00000187045,"Transmembrane protease, serine 6",22,37065436-37109563,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Liver cancer:8.16e-6 (favourable),Group enriched,Group enriched,6,liver: 40.8;testis: 8.6,stomach: 4.0,Cell line enhanced,,Hep G2: 3.6;SCLC-21H: 10.1
307,TRIM58,BIA2,ENSG00000162722,Tripartite motif containing 58,1,247857199-247878205,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA023637,Uncertain,,,,,Mixed,Group enriched,6,bone marrow: 16.1;placenta: 6.8;testis: 5.4;thyroid gland: 22.0,prostate: 2.1,Group enriched,5.0,HAP1: 15.0;HEL: 35.6;K-562: 19.9;PC-3: 34.5;U-2 OS: 31.0;U-937: 8.8;WM-115: 38.8
308,TTC6,"C14orf25, NCRNA00291",ENSG00000139865,Tetratricopeptide repeat domain 6,14,37595847-38041442,Predicted intracellular proteins,Evidence at protein level,HPA069293,,,Approved,Centrosome,,Group enriched,Group enriched,6,breast: 10.5;prostate: 28.3;testis: 10.4,stomach: 2.6,Cell line enhanced,,Hep G2: 5.7;MCF7: 9.4;RT4: 6.7;T-47d: 21.4
309,TUBA8,TUBAL2,ENSG00000183785,Tubulin alpha 8,22,18110331-18146554,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043684, CAB046031, HPA063394",Approved,,Supported,Microtubules,,Not detected,Group enriched,6,cerebral cortex: 28.6;heart muscle: 83.0;skeletal muscle: 121.7;testis: 47.4,thyroid gland: 11.2,Group enriched,5.0,NB-4: 19.8;SCLC-21H: 17.4;TIME: 31.1
310,WNK3,PRKWNK3,ENSG00000196632,WNK lysine deficient protein kinase 3,X,54192823-54358642,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA077678,,,Approved,Vesicles,,Mixed,Group enriched,6,epididymis: 14.3;testis: 18.6,ovary: 2.6,Cell line enhanced,,AF22: 4.4;HAP1: 5.4;NTERA-2: 9.1;SiHa: 4.8;U-2 OS: 4.1
311,ACE2,,ENSG00000130234,Angiotensin I converting enzyme 2,X,15561033-15602148,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA000288, CAB026174",Enhanced,,,,"Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable)",Tissue enhanced,Group enriched,5,duodenum: 181.1;gallbladder: 100.2;kidney: 94.0;small intestine: 261.1;testis: 93.0,heart muscle: 27.9,Cell line enhanced,,HaCaT: 1.1
312,ALS2CR12,,ENSG00000155749,Amyotrophic lateral sclerosis 2 chromosome region 12,2,201288271-201357398,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA035793,,,Approved,Plasma membrane<br>Cytosol,,Not detected,Group enriched,5,fallopian tube: 15.0;testis: 31.8,lung: 4.2,Cell line enhanced,,U-2197: 4.3
313,AOC2,"DAO2, RAO",ENSG00000131480,"Amine oxidase, copper containing 2",17,42844600-42850707,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA057779,Uncertain,,,,Urothelial cancer:2.47e-4 (favourable),Tissue enhanced,Group enriched,5,adipose tissue: 6.2;testis: 5.8,spleen: 1.2,Cell line enhanced,,ASC diff: 7.7
314,C11orf88,FLJ46266,ENSG00000183644,Chromosome 11 open reading frame 88,11,111514785-111537031,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,5,fallopian tube: 141.7;testis: 39.5,lung: 17.8,Cell line enhanced,,CACO-2: 1.3;Karpas-707: 1.2
315,CCDC114,"CILD20, FLJ32926",ENSG00000105479,Coiled-coil domain containing 114,19,48296457-48321894,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA042524,Approved,,,,,Tissue enhanced,Group enriched,5,fallopian tube: 6.3;testis: 5.7,lung: 1.1,Cell line enhanced,,U-266/70: 1.0
316,CCDC157,,ENSG00000187860,Coiled-coil domain containing 157,22,30356635-30378658,Predicted intracellular proteins,Evidence at protein level,HPA042943,Uncertain,,,,,Mixed,Group enriched,5,fallopian tube: 12.0;testis: 28.4,thyroid gland: 3.9,Mixed,,
317,CD300LG,"CLM9, Trem4",ENSG00000161649,CD300 molecule like family member g,17,43847148-43863629,"CD markers, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Mixed,Group enriched,5,adipose tissue: 143.0;placenta: 86.4;testis: 33.9,lung: 17.3,Not detected,,
318,CFAP100,"CCDC37, FLJ40083, MIA1",ENSG00000163885,Cilia and flagella associated protein 100,3,126394939-126436556,Predicted intracellular proteins,Evidence at protein level,HPA046354,Enhanced,,,,,Tissue enhanced,Group enriched,5,fallopian tube: 43.4;testis: 34.5,lung: 7.4,Not detected,,
319,CFAP58,"bA554P13.1, C10orf80, CCDC147, FLJ35908",ENSG00000120051,Cilia and flagella associated protein 58,10,104353764-104455090,Predicted intracellular proteins,Evidence at protein level,"HPA036555, HPA036556",Uncertain,,Approved,Nucleus,,Mixed,Group enriched,5,fallopian tube: 13.3;testis: 23.5,"cervix, uterine: 3.3",Cell line enhanced,,U-2 OS: 6.5
320,DBX2,FLJ16139,ENSG00000185610,Developing brain homeobox 2,12,45014672-45051099,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA066053,Uncertain,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 4.1;testis: 1.2,skin: 0.5,Not detected,,
321,DCST1,FLJ32785,ENSG00000163357,DC-STAMP domain containing 1,1,155033824-155050930,Predicted membrane proteins,Evidence at protein level,HPA060314,Uncertain,,,,,Not detected,Group enriched,5,skin: 3.7;testis: 6.1,small intestine: 0.9,Cell line enhanced,,HaCaT: 1.8;RPMI-8226: 1.7
322,DNAH3,"DKFZp434N074, DLP3, Dnahc3b, Hsadhc3",ENSG00000158486,Dynein axonemal heavy chain 3,16,20933111-21159441,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA062493,,,Approved,Nuclear membrane<br>Intermediate filaments,,Mixed,Group enriched,5,fallopian tube: 8.1;testis: 6.0,lung: 1.3,Not detected,,
323,DNAJC18,MGC29463,ENSG00000170464,DnaJ heat shock protein family (Hsp40) member C18,5,139408588-139444491,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA036538, HPA060154",Approved,,Supported,Cell Junctions,Pancreatic cancer:5.89e-4 (favourable),Mixed,Group enriched,5,cerebral cortex: 30.2;testis: 115.6,ovary: 13.8,Mixed,,
324,EFCAB12,C3orf25,ENSG00000172771,EF-hand calcium binding domain 12,3,129401321-129428651,Predicted intracellular proteins,Evidence at protein level,HPA037694,Uncertain,Supported,,,,Mixed,Group enriched,5,fallopian tube: 31.3;testis: 6.7,prostate: 3.7,Cell line enhanced,,Hep G2: 1.0;SCLC-21H: 1.0
325,EFCAB6,"dJ185D5.1, DJBP, FLJ23588, HSCBCIP1, KIAA1672",ENSG00000186976,EF-hand calcium binding domain 6,22,43528744-43812337,Predicted intracellular proteins,Evidence at protein level,HPA003098,,,Uncertain,Nucleoplasm,,Mixed,Group enriched,5,fallopian tube: 12.3;testis: 44.2,thyroid gland: 5.1,Mixed,,
326,FAM178B,LOC51252,ENSG00000168754,Family with sequence similarity 178 member B,2,96875882-96986592,Predicted intracellular proteins,Evidence at transcript level,"HPA042516, HPA062110",Uncertain,,Uncertain,Nuclear speckles<br>Golgi apparatus,,Tissue enriched,Group enriched,5,bone marrow: 11.4;epididymis: 6.7;spleen: 16.7;testis: 7.4,fallopian tube: 2.0,Cell line enhanced,,K-562: 23.0;RPMI-8226: 19.2;WM-115: 26.6
327,FANK1,,ENSG00000203780,Fibronectin type III and ankyrin repeat domains 1,10,125896539-126009592,Predicted intracellular proteins,Evidence at protein level,HPA038413,,,Supported,Nucleoplasm,Endometrial cancer:3.83e-4 (favourable),Mixed,Group enriched,5,fallopian tube: 55.3;testis: 92.6,epididymis: 14.3,Cell line enhanced,,CAPAN-2: 16.8;RPTEC TERT1: 10.1
328,FBXL13,"DRC6, Fbl13, MGC21636",ENSG00000161040,F-box and leucine rich repeat protein 13,7,102813230-103074843,Predicted intracellular proteins,Evidence at protein level,HPA057232,Uncertain,,,,,Mixed,Group enriched,5,fallopian tube: 7.9;testis: 37.4,stomach: 4.5,Cell line enhanced,,HUVEC TERT2: 11.6;U-266/84: 12.5;U-87 MG: 9.3;U-937: 9.5
329,GCNA,"ACRC, NAAR1",ENSG00000147174,Germ cell nuclear acidic peptidase,X,71578411-71613583,Predicted intracellular proteins,Evidence at protein level,HPA023476,Enhanced,,Approved,Vesicles,,Mixed,Group enriched,5,adrenal gland: 5.9;testis: 20.6,spleen: 2.4,Mixed,,
330,GDF9,,ENSG00000164404,Growth differentiation factor 9,5,132861181-132866884,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA069146,Supported,,,,,Tissue enriched,Group enriched,5,epididymis: 5.0;testis: 14.1,thyroid gland: 1.8,Mixed,,
331,HIST1H2BB,"H2B/f, H2BFF",ENSG00000276410,Histone cluster 1 H2B family member b,6,26043277-26043657,Predicted intracellular proteins,Evidence at protein level,"HPA042205, HPA043013, HPA048671",Supported,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,5,bone marrow: 1.1;testis: 3.1,"esophagus,lymph node: 0.3",Cell line enhanced,,MOLT-4: 1.9;THP-1: 1.9;U-266/84: 2.2
332,HIST1H3A,"H3/A, H3FA",ENSG00000275714,Histone cluster 1 H3 family member a,6,26020490-26020900,Predicted intracellular proteins,Evidence at protein level,HPA042570,Supported,,,,,Mixed,Group enriched,5,bone marrow: 6.7;epididymis: 1.8;testis: 3.7,lung: 0.7,Cell line enhanced,,U-2 OS: 5.3
333,IGDCC3,"HsT18880, PUNC",ENSG00000174498,Immunoglobulin superfamily DCC subclass member 3,15,65327127-65378040,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA015246,Approved,,,,,Tissue enhanced,Group enriched,5,cerebral cortex: 3.3;parathyroid gland: 14.6;placenta: 8.5;testis: 5.0,thyroid gland: 1.5,Cell line enhanced,,AF22: 103.7;CACO-2: 22.5;Hep G2: 58.8
334,ISLR2,KIAA1465,ENSG00000167178,Immunoglobulin superfamily containing leucine rich repeat 2,15,74100311-74138540,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012930, HPA067333",Uncertain,,,,,Mixed,Group enriched,5,cerebral cortex: 31.1;testis: 14.8,endometrium: 4.5,Group enriched,13.0,SCLC-21H: 68.2;SH-SY5Y: 91.6
335,KIAA1210,,ENSG00000250423,KIAA1210,X,119078635-119150579,Predicted intracellular proteins,Evidence at protein level,"HPA000551, HPA048322",Enhanced,,,,,Tissue enhanced,Group enriched,5,epididymis: 47.9;seminal vesicle: 27.4;testis: 58.3,fallopian tube: 8.6,Not detected,,
336,LEXM,"C1orf177, FLJ40201, LEM",ENSG00000162398,Lymphocyte expansion molecule,1,54806063-54842252,Predicted intracellular proteins,Evidence at protein level,"HPA035889, HPA035890",Uncertain,,,,,Mixed,Group enriched,5,esophagus: 10.5;testis: 7.0,duodenum: 1.6,Not detected,,
337,LRRC43,MGC35140,ENSG00000158113,Leucine rich repeat containing 43,12,122167738-122203471,Predicted intracellular proteins,Evidence at transcript level,"HPA039425, HPA047606",Uncertain,,Approved,Golgi apparatus<br>Vesicles,,Mixed,Group enriched,5,fallopian tube: 30.3;testis: 8.5,parathyroid gland: 3.6,Cell line enhanced,,HUVEC TERT2: 2.2;SCLC-21H: 2.5
338,LYG1,SALW1939,ENSG00000144214,Lysozyme g1,2,99284238-99304742,Predicted secreted proteins,Evidence at transcript level,,,,,,Renal cancer:8.44e-4 (favourable),Tissue enriched,Group enriched,5,kidney: 22.0;testis: 4.8,breast: 2.5,Mixed,,
339,MBNL3,"CHCR, FLJ11316, MBLX39, MBXL",ENSG00000076770,Muscleblind like splicing regulator 3,X,132369317-132489968,Predicted intracellular proteins,Evidence at protein level,HPA001584,Enhanced,,Approved,Golgi apparatus<br>Vesicles,Endometrial cancer:1.57e-4 (unfavourable),Expressed in all,Group enriched,5,placenta: 242.1;testis: 81.4,liver: 30.6,Cell line enhanced,,CACO-2: 102.2;Hep G2: 116.6
340,MDH1B,"FLJ25341, RP11-95H11",ENSG00000138400,Malate dehydrogenase 1B,2,206737763-206765547,Predicted intracellular proteins,Evidence at transcript level,HPA073761,Approved,,,,,Mixed,Group enriched,5,fallopian tube: 35.3;testis: 43.8,parathyroid gland: 7.5,Cell line enhanced,,SCLC-21H: 4.0
341,MGAT4C,HGNT-IV-H,ENSG00000182050,MGAT4 family member C,12,85955666-86838904,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA016418,Approved,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 5.9;epididymis: 6.7;testis: 5.5;thyroid gland: 15.9,adrenal gland: 1.6,Group enriched,13.0,NTERA-2: 8.7;SCLC-21H: 4.4
342,NMBR,"BB1, BB1R",ENSG00000135577,Neuromedin B receptor,6,142058330-142088799,"G-protein coupled receptors, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA026665,,,Supported,Plasma membrane<br>Cytosol,,Not detected,Group enriched,5,fallopian tube: 1.4;testis: 2.6,cerebral cortex: 0.3,Not detected,,
343,OVCH1,OVCH,ENSG00000187950,Ovochymase 1,12,29412474-29497686,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA040253,Uncertain,,,,,Not detected,Group enriched,5,lung: 6.8;testis: 4.3;thyroid gland: 1.7,spleen: 0.8,Group enriched,6.0,Daudi: 3.9;HEL: 1.0
344,OVOL3,HOVO3,ENSG00000105261,Ovo like zinc finger 3,19,36111151-36113711,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Not detected,Group enriched,5,skin: 1.0;testis: 2.8,appendix: 0.3,Cell line enhanced,,U-266/84: 2.1
345,PABPC1L2A,RBM32A,ENSG00000186288,Poly(A) binding protein cytoplasmic 1 like 2A,X,73077276-73079512,Predicted intracellular proteins,Evidence at transcript level,HPA041573,Approved,,,,,Tissue enriched,Group enriched,5,adrenal gland: 2.0;cerebral cortex: 6.7;prostate: 3.6;testis: 2.8,epididymis: 0.7,Cell line enhanced,,HeLa: 2.6;NTERA-2: 1.4
346,PIAS2,"miz, PIASX-ALPHA, PIASX-BETA, ZMIZ4",ENSG00000078043,Protein inhibitor of activated STAT 2,18,46803224-46920160,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA068792,Enhanced,,Supported,Nucleoplasm,Thyroid cancer:1.27e-4 (unfavourable),Expressed in all,Group enriched,5,parathyroid gland: 28.5;testis: 119.6,"cerebral cortex,thyroid gland: 13.8",Mixed,,
347,PPM1E,"CaMKP-N, KIAA1072, POPX1, PP2CH",ENSG00000175175,"Protein phosphatase, Mg2+/Mn2+ dependent 1E",17,58755869-58985176,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA018462, HPA019263",Approved,,Approved,Nucleus<br>Nucleoli,,Tissue enhanced,Group enriched,5,adrenal gland: 7.3;cerebral cortex: 20.5;testis: 12.1,fallopian tube: 2.4,Cell line enhanced,,AF22: 12.1;HAP1: 20.6;SCLC-21H: 10.7;SH-SY5Y: 19.9
348,PPP1R17,"C7orf16, GSBS",ENSG00000106341,Protein phosphatase 1 regulatory subunit 17,7,31686715-31708455,Predicted intracellular proteins,Evidence at protein level,"HPA047819, HPA073123",Supported,,Supported,Nucleoplasm,,Tissue enhanced,Group enriched,5,adrenal gland: 4.8;cerebral cortex: 2.6;testis: 1.1,lung: 0.5,Group enriched,225.0,NTERA-2: 33.8;SCLC-21H: 120.1
349,RGS8,"MGC119067, MGC119068, MGC119069",ENSG00000135824,Regulator of G-protein signaling 8,1,182641816-182684576,Predicted intracellular proteins,Evidence at protein level,HPA076764,Supported,,,,,Group enriched,Group enriched,5,cerebral cortex: 5.3;testis: 4.9;thyroid gland: 11.3,adrenal gland: 1.3,Group enriched,5.0,AF22: 5.6;SCLC-21H: 18.7
350,RP11-723O4.6,,ENSG00000187695,Uncharacterized protein FLJ43738 ,3,128909874-128971330,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Group enriched,5,fallopian tube: 10.7;skin: 6.8;testis: 20.3,lung: 2.4,Cell line enhanced,,HAP1: 4.6;HL-60: 4.8
351,SLC1A6,EAAT4,ENSG00000105143,Solute carrier family 1 member 6,19,14950034-15022990,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA041505, HPA044066",Enhanced,,Uncertain,Intermediate filaments,Urothelial cancer:6.88e-6 (unfavourable),Tissue enriched,Group enriched,5,cerebral cortex: 16.2;skin: 8.9;testis: 36.9,epididymis: 3.7,Group enriched,5.0,HAP1: 7.6;NTERA-2: 6.0;U-698: 19.3
352,SPACA9,"C9orf9, Mast",ENSG00000165698,Sperm acrosome associated 9,9,132878027-132890201,Predicted intracellular proteins,Evidence at protein level,"HPA022243, HPA051600",Enhanced,,Approved,Mitochondria,"Renal cancer:8.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)",Expressed in all,Group enriched,5,epididymis: 90.3;fallopian tube: 63.1;testis: 130.1,thyroid gland: 18.0,Mixed,,
353,SPATC1,"MGC61633, SPATA15, SPERIOLIN",ENSG00000186583,Spermatogenesis and centriole associated 1,8,144012414-144047085,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,5,bone marrow: 6.2;testis: 21.7,appendix: 2.5,Cell line enriched,8.0,U-937: 6.3
354,SPATS1,"FLJ25442, SPATA8, SRSP1",ENSG00000249481,Spermatogenesis associated serine rich 1,6,44342660-44377167,Predicted intracellular proteins,Evidence at transcript level,"HPA030897, HPA049722",Approved,,Approved,Nucleoplasm,,Not detected,Group enriched,5,fallopian tube: 14.2;testis: 45.3,epididymis: 5.6,Cell line enriched,60.0,SK-MEL-30: 5.9
355,SYT14,"FLJ34198, sytXIV",ENSG00000143469,Synaptotagmin 14,1,209938174-210171389,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA036963,,,Supported,Vesicles,,Tissue enhanced,Group enriched,5,cerebral cortex: 3.0;testis: 6.7;thyroid gland: 9.8,adrenal gland: 1.3,Cell line enhanced,,BJ hTERT+: 10.5;SCLC-21H: 7.8;TIME: 8.9;U-138 MG: 7.9
356,TCF15,"bHLHa40, EC2, PARAXIS",ENSG00000125878,Transcription factor 15 (basic helix-loop-helix),20,603797-610398,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA050998, HPA060221",Uncertain,,Supported,Nuclear speckles,Ovarian cancer:3.25e-4 (unfavourable),Mixed,Group enriched,5,adipose tissue: 6.3;heart muscle: 3.4;placenta: 4.8;skeletal muscle: 4.6;testis: 1.3,lung: 0.7,Cell line enhanced,,HEL: 9.5;HMC-1: 14.7
357,TGM7,TGMZ,ENSG00000159495,Transglutaminase 7,15,43276280-43302255,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at transcript level,,,,,,,Tissue enriched,Group enriched,5,testis: 1.5;tonsil: 1.5,esophagus: 0.2,Cell line enriched,33.0,EFO-21: 3.3
358,TMEM132E,DFNB99,ENSG00000181291,Transmembrane protein 132E,17,34580749-34639318,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA070608,Approved,,,,Renal cancer:1.55e-4 (unfavourable),Group enriched,Group enriched,5,cerebral cortex: 4.8;duodenum: 1.7;kidney: 3.2;small intestine: 1.0;testis: 1.5,"cervix, uterine: 0.4",Cell line enriched,7.0,RPMI-8226: 31.6
359,TMEM215,,ENSG00000188133,Transmembrane protein 215,9,32783499-32787399,Predicted membrane proteins,Evidence at protein level,"HPA052804, HPA063207",Uncertain,,Supported,Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles,,Tissue enriched,Group enriched,5,"cervix, uterine: 1.0;endometrium: 4.8;testis: 4.2;thyroid gland: 1.8",cerebral cortex: 0.5,Cell line enhanced,,NTERA-2: 1.9
360,TUBB1,dJ543J19.4,ENSG00000101162,Tubulin beta 1 class VI,20,59019254-59026654,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004286, HPA043640, HPA046280",Approved,,,,,Not detected,Group enriched,5,bone marrow: 4.8;lung: 2.1;placenta: 1.5;spleen: 5.6;testis: 1.5,gallbladder: 0.5,Cell line enriched,20.0,HEL: 24.9
361,USP6,"HRP1, Tre-2, TRE17, Tre2, TRESMCR",ENSG00000129204,Ubiquitin specific peptidase 6,17,5116438-5175034,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA046969,,,Uncertain,Vesicles,,Tissue enriched,Group enriched,5,ovary: 3.5;skeletal muscle: 7.5;testis: 17.1,smooth muscle: 1.8,Mixed,,
362,WASF1,"KIAA0269, SCAR1, WAVE, WAVE1",ENSG00000112290,WAS protein family member 1,6,110099819-110180004,Predicted intracellular proteins,Evidence at protein level,"HPA004105, CAB022161",Approved,Approved,,,"Liver cancer:2.82e-8 (unfavourable), Renal cancer:2.79e-5 (unfavourable)",Expressed in all,Group enriched,5,cerebral cortex: 138.9;testis: 149.9,ovary: 27.8,Mixed,,
363,WDR78,"DIC4, FLJ23129",ENSG00000152763,WD repeat domain 78,1,66812885-66924887,Predicted intracellular proteins,Evidence at protein level,,,,,,Renal cancer:9.60e-5 (favourable),Mixed,Group enriched,5,fallopian tube: 43.8;testis: 62.9,parathyroid gland: 10.2,Cell line enhanced,,RPTEC TERT1: 8.6
